97)PC$ 8 )PG 3 "
M &UL4$L! A0#% @ /(@*5^]@XE-4
M!P 0B0 !@ ("!#0@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(@*5WL&59XW! 00\ !@
M ("!HQ< 'AL+W=OTBE$S\P0 &\9 8 " @1 < !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#
M% @ /(@*5Q!2&TW<$@ !38 !@ ("!V"< 'AL+W=O
M$2JET#P, .T'
M 8 " @>HZ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ /(@*5X=_XE5"
M @ )04 !D ("!HD( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(@*5X//'SE% P 2 < !D
M ("!I$P 'AL+W=O&PO=V]R
M:W-H965T$"Q-22P4 (,
M 9 " @1M? !X;"]W;W)K&UL
M4$L! A0#% @ /(@*5SXQA<:3#P WRT !D ("!G60
M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @
M/(@*5R"QX*WB P @PH !D ("!4'L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ /(@*5P*(!>[2 @ [ @ !D
M ("!HY$ 'AL+W=O&PO=V]R:W-H
M965T&UL4$L!
M A0#% @ /(@*5]5DHERY!0 ,20 !D ("!?)P 'AL
M+W=O&PO=V]R:W-H965TQ&B./IP( %,& 9 "
M@0.E !X;"]W;W)K&UL4$L! A0#% @ /(@*
M5UC8<8N@ @ 1 8 !D ("!X:< 'AL+W=O&PO=V]R:W-H965TY]C).,P, $H3 - " 7JM !X;"]S='EL
M97,N>&UL4$L! A0#% @ /(@*5Y>*NQS $P( L
M ( !V+ %]R96QS+RYR96QS4$L! A0#% @ /(@*5V5GRK\P P [Q4
M \ ( !P;$ 'AL+W=O*$X-D8P$ +<3 : " 1ZU !X;"]?7!E&UL4$L%!@ H
- "@ SPH '.X $!
end
XML
45
Show.js
IDEA: XBRL DOCUMENT
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
XML
46
report.css
IDEA: XBRL DOCUMENT
/* Updated 2009-11-04 */
/* v2.2.0.24 */
/* DefRef Styles */
..report table.authRefData{
background-color: #def;
border: 2px solid #2F4497;
font-size: 1em;
position: absolute;
}
..report table.authRefData a {
display: block;
font-weight: bold;
}
..report table.authRefData p {
margin-top: 0px;
}
..report table.authRefData .hide {
background-color: #2F4497;
padding: 1px 3px 0px 0px;
text-align: right;
}
..report table.authRefData .hide a:hover {
background-color: #2F4497;
}
..report table.authRefData .body {
height: 150px;
overflow: auto;
width: 400px;
}
..report table.authRefData table{
font-size: 1em;
}
/* Report Styles */
..pl a, .pl a:visited {
color: black;
text-decoration: none;
}
/* table */
..report {
background-color: white;
border: 2px solid #acf;
clear: both;
color: black;
font: normal 8pt Helvetica, Arial, san-serif;
margin-bottom: 2em;
}
..report hr {
border: 1px solid #acf;
}
/* Top labels */
..report th {
background-color: #acf;
color: black;
font-weight: bold;
text-align: center;
}
..report th.void {
background-color: transparent;
color: #000000;
font: bold 10pt Helvetica, Arial, san-serif;
text-align: left;
}
..report .pl {
text-align: left;
vertical-align: top;
white-space: normal;
width: 200px;
white-space: normal; /* word-wrap: break-word; */
}
..report td.pl a.a {
cursor: pointer;
display: block;
width: 200px;
overflow: hidden;
}
..report td.pl div.a {
width: 200px;
}
..report td.pl a:hover {
background-color: #ffc;
}
/* Header rows... */
..report tr.rh {
background-color: #acf;
color: black;
font-weight: bold;
}
/* Calendars... */
..report .rc {
background-color: #f0f0f0;
}
/* Even rows... */
..report .re, .report .reu {
background-color: #def;
}
..report .reu td {
border-bottom: 1px solid black;
}
/* Odd rows... */
..report .ro, .report .rou {
background-color: white;
}
..report .rou td {
border-bottom: 1px solid black;
}
..report .rou table td, .report .reu table td {
border-bottom: 0px solid black;
}
/* styles for footnote marker */
..report .fn {
white-space: nowrap;
}
/* styles for numeric types */
..report .num, .report .nump {
text-align: right;
white-space: nowrap;
}
..report .nump {
padding-left: 2em;
}
..report .nump {
padding: 0px 0.4em 0px 2em;
}
/* styles for text types */
..report .text {
text-align: left;
white-space: normal;
}
..report .text .big {
margin-bottom: 1em;
width: 17em;
}
..report .text .more {
display: none;
}
..report .text .note {
font-style: italic;
font-weight: bold;
}
..report .text .small {
width: 10em;
}
..report sup {
font-style: italic;
}
..report .outerFootnotes {
font-size: 1em;
}
XML
47
FilingSummary.xml
IDEA: XBRL DOCUMENT
3.23.2
html
70
154
1
false
21
0
false
5
false
false
R1.htm
100000 - Document - Cover Page
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CoverPage
Cover Page
Cover
1
false
false
R2.htm
100010 - Statement - Condensed Balance Sheets
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets
Condensed Balance Sheets
Statements
2
false
false
R3.htm
100020 - Statement - Condensed Balance Sheets (Parenthetical)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical
Condensed Balance Sheets (Parenthetical)
Statements
3
false
false
R4.htm
100030 - Statement - Condensed Statements of Operations (Unaudited)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited
Condensed Statements of Operations (Unaudited)
Statements
4
false
false
R5.htm
100040 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited
Condensed Statements of Changes in Stockholders' Equity (Unaudited)
Statements
5
false
false
R6.htm
100050 - Statement - Condensed Statements of Cash Flows (Unaudited)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited
Condensed Statements of Cash Flows (Unaudited)
Statements
6
false
false
R7.htm
100060 - Disclosure - Organization and Summary of Significant Accounting Policies
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPolicies
Organization and Summary of Significant Accounting Policies
Notes
7
false
false
R8.htm
100070 - Disclosure - Accrued Liabilities and Other Current Liabilities
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilities
Accrued Liabilities and Other Current Liabilities
Notes
8
false
false
R9.htm
100080 - Disclosure - Debt, Net
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNet
Debt, Net
Notes
9
false
false
R10.htm
100090 - Disclosure - Preferred Stock
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStock
Preferred Stock
Notes
10
false
false
R11.htm
100100 - Disclosure - Net Loss Per Share
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShare
Net Loss Per Share
Notes
11
false
false
R12.htm
100110 - Disclosure - Fair Value of Financial Instruments
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstruments
Fair Value of Financial Instruments
Notes
12
false
false
R13.htm
100120 - Disclosure - Income Taxes
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxes
Income Taxes
Notes
13
false
false
R14.htm
100130 - Disclosure - Commitments and Contingencies
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingencies
Commitments and Contingencies
Notes
14
false
false
R15.htm
100140 - Disclosure - Subsequent Events
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/SubsequentEvents
Subsequent Events
Notes
15
false
false
R16.htm
100150 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies
Organization and Summary of Significant Accounting Policies (Policies)
Policies
http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPolicies
16
false
false
R17.htm
100170 - Disclosure - Net Loss Per Share (Tables)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareTables
Net Loss Per Share (Tables)
Tables
http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShare
17
false
false
R18.htm
100180 - Disclosure - Fair Value of Financial Instruments (Tables)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsTables
Fair Value of Financial Instruments (Tables)
Tables
http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstruments
18
false
false
R19.htm
100190 - Disclosure - Commitments and Contingencies (Tables)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables
Commitments and Contingencies (Tables)
Tables
http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingencies
19
false
false
R20.htm
100200 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
Details
20
false
false
R21.htm
100210 - Disclosure - Debt, Net - Additional Information (Details)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails
Debt, Net - Additional Information (Details)
Details
21
false
false
R22.htm
100230 - Disclosure - Accrued Liabilities and Other Current Liabilities - Additional Information (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail
Accrued Liabilities and Other Current Liabilities - Additional Information (Detail)
Details
22
false
false
R23.htm
100240 - Disclosure - Preferred Stock - Additional Information (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail
Preferred Stock - Additional Information (Detail)
Details
23
false
false
R24.htm
100250 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail
Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)
Details
24
false
false
R25.htm
100260 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail
Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)
Details
25
false
false
R26.htm
100270 - Disclosure - Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail
Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)
Details
26
false
false
R27.htm
100280 - Disclosure - Income Taxes - Additional Information (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxesAdditionalInformationDetail
Income Taxes - Additional Information (Detail)
Details
27
false
false
R28.htm
100290 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail
Commitments and Contingencies - Additional Information (Detail)
Details
28
false
false
R29.htm
100300 - Disclosure - Commitments and Contingencies - Summary of components of the lease expense (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfTheLeaseExpenseDetail
Commitments and Contingencies - Summary of components of the lease expense (Detail)
Details
29
false
false
R30.htm
100310 - Disclosure - Commitments and Contingencies - Summary of supplemental cash flow information related to lease (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail
Commitments and Contingencies - Summary of supplemental cash flow information related to lease (Detail)
Details
30
false
false
R31.htm
100320 - Disclosure - Commitments and Contingencies - Supplemental balance sheet information related to lease (Detail)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail
Commitments and Contingencies - Supplemental balance sheet information related to lease (Detail)
Details
31
false
false
R32.htm
100340 - Disclosure - Subsequent Events - Additional Information (Details)
Sheet
http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails
Subsequent Events - Additional Information (Details)
Details
32
false
false
All Reports
Book
All Reports
hcwb-20230331.htm
hcwb-20230331.xsd
hcwb-20230331_cal.xml
hcwb-20230331_def.xml
hcwb-20230331_lab.xml
hcwb-20230331_pre.xml
hcwb-ex31_1.htm
hcwb-ex31_2.htm
hcwb-ex32_1.htm
hcwb-ex32_2.htm
http://fasb.org/us-gaap/2023
http://xbrl.sec.gov/dei/2023
true
true
JSON
49
MetaLinks.json
IDEA: XBRL DOCUMENT
{
"instance": {
"hcwb-20230331.htm": {
"axisCustom": 2,
"axisStandard": 13,
"baseTaxonomies": {
"http://fasb.org/us-gaap/2023": 270,
"http://xbrl.sec.gov/dei/2023": 32
},
"contextCount": 70,
"dts": {
"calculationLink": {
"local": [
"hcwb-20230331_cal.xml"
]
},
"definitionLink": {
"local": [
"hcwb-20230331_def.xml"
]
},
"inline": {
"local": [
"hcwb-20230331.htm"
]
},
"labelLink": {
"local": [
"hcwb-20230331_lab.xml"
]
},
"presentationLink": {
"local": [
"hcwb-20230331_pre.xml"
]
},
"schema": {
"local": [
"hcwb-20230331.xsd"
],
"remote": [
"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
"http://www.xbrl.org/2003/xl-2003-12-31.xsd",
"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
"http://www.xbrl.org/2005/xbrldt-2005.xsd",
"http://www.xbrl.org/2006/ref-2006-02-27.xsd",
"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
"http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
"https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
"https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
"https://xbrl.sec.gov/country/2023/country-2023.xsd",
"https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
]
}
},
"elementCount": 327,
"entityCount": 1,
"hidden": {
"http://fasb.org/us-gaap/2023": 2,
"http://xbrl.sec.gov/dei/2023": 4,
"total": 6
},
"keyCustom": 6,
"keyStandard": 148,
"memberCustom": 8,
"memberStandard": 12,
"nsprefix": "hcwb",
"nsuri": "http://hcwbiologics.com/20230331",
"report": {
"R1": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "document",
"isDefault": "true",
"longName": "100000 - Document - Cover Page",
"menuCat": "Cover",
"order": "1",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CoverPage",
"shortName": "Cover Page",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "dei:DocumentType",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R10": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100090 - Disclosure - Preferred Stock",
"menuCat": "Notes",
"order": "10",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStock",
"shortName": "Preferred Stock",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:PreferredStockTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R11": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100100 - Disclosure - Net Loss Per Share",
"menuCat": "Notes",
"order": "11",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShare",
"shortName": "Net Loss Per Share",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:EarningsPerShareTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R12": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100110 - Disclosure - Fair Value of Financial Instruments",
"menuCat": "Notes",
"order": "12",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstruments",
"shortName": "Fair Value of Financial Instruments",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:FairValueDisclosuresTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R13": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100120 - Disclosure - Income Taxes",
"menuCat": "Notes",
"order": "13",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxes",
"shortName": "Income Taxes",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:IncomeTaxDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R14": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100130 - Disclosure - Commitments and Contingencies",
"menuCat": "Notes",
"order": "14",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingencies",
"shortName": "Commitments and Contingencies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:CommitmentsDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R15": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100140 - Disclosure - Subsequent Events",
"menuCat": "Notes",
"order": "15",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/SubsequentEvents",
"shortName": "Subsequent Events",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:SubsequentEventsTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R16": {
"firstAnchor": {
"ancestors": [
"div",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100150 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
"menuCat": "Policies",
"order": "16",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
"shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
"subGroupType": "policies",
"uniqueAnchor": {
"ancestors": [
"div",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R17": {
"firstAnchor": {
"ancestors": [
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100170 - Disclosure - Net Loss Per Share (Tables)",
"menuCat": "Tables",
"order": "17",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareTables",
"shortName": "Net Loss Per Share (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R18": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100180 - Disclosure - Fair Value of Financial Instruments (Tables)",
"menuCat": "Tables",
"order": "18",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsTables",
"shortName": "Fair Value of Financial Instruments (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R19": {
"firstAnchor": {
"ancestors": [
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100190 - Disclosure - Commitments and Contingencies (Tables)",
"menuCat": "Tables",
"order": "19",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables",
"shortName": "Commitments and Contingencies (Tables)",
"subGroupType": "tables",
"uniqueAnchor": {
"ancestors": [
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:LeaseCostTableTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R2": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100010 - Statement - Condensed Balance Sheets",
"menuCat": "Statements",
"order": "2",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"shortName": "Condensed Balance Sheets",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"lang": null,
"name": "us-gaap:ReceivablesNetCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R20": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100200 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
"menuCat": "Details",
"order": "20",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:InvestmentPolicyTextBlock",
"div",
"us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "INF",
"lang": null,
"name": "hcwb:InvestmentImpairmentCharges",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R21": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:DebtDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:LongTermDebtCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100210 - Disclosure - Debt, Net - Additional Information (Details)",
"menuCat": "Details",
"order": "21",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails",
"shortName": "Debt, Net - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:DebtDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:LongTermDebtCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R22": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100230 - Disclosure - Accrued Liabilities and Other Current Liabilities - Additional Information (Detail)",
"menuCat": "Details",
"order": "22",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"shortName": "Accrued Liabilities and Other Current Liabilities - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "-5",
"lang": null,
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R23": {
"firstAnchor": {
"ancestors": [
"us-gaap:PreferredStockSharesAuthorized",
"span",
"p",
"us-gaap:PreferredStockTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100240 - Disclosure - Preferred Stock - Additional Information (Detail)",
"menuCat": "Details",
"order": "23",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"shortName": "Preferred Stock - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:PreferredStockSharesAuthorized",
"span",
"p",
"us-gaap:PreferredStockTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:PreferredStockSharesAuthorized",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
}
},
"R24": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100250 - Disclosure - Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)",
"menuCat": "Details",
"order": "24",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"shortName": "Net Loss Per Share - Summary of Basic and Diluted Net Income (Loss) Per Common Share (Detail)",
"subGroupType": "details",
"uniqueAnchor": null
},
"R25": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100260 - Disclosure - Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)",
"menuCat": "Details",
"order": "25",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail",
"shortName": "Net Loss Per Share - Summary of Outstanding Potentially Dilutive Securities (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"div",
"us-gaap:EarningsPerShareTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
}
},
"R26": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"ix:continuation",
"div",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100270 - Disclosure - Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
"menuCat": "Details",
"order": "26",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail",
"shortName": "Fair Value of Financial Instruments - Summary of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"ix:continuation",
"div",
"us-gaap:FairValueDisclosuresTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AssetsFairValueDisclosure",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R27": {
"firstAnchor": {
"ancestors": [
"us-gaap:IncomeTaxExpenseBenefit",
"span",
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100280 - Disclosure - Income Taxes - Additional Information (Detail)",
"menuCat": "Details",
"order": "27",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxesAdditionalInformationDetail",
"shortName": "Income Taxes - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"us-gaap:IncomeTaxExpenseBenefit",
"span",
"p",
"us-gaap:IncomeTaxDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:IncomeTaxExpenseBenefit",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R28": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AreaOfLand",
"reportCount": 1,
"unique": true,
"unitRef": "U_sqft",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100290 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
"menuCat": "Details",
"order": "28",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"shortName": "Commitments and Contingencies - Additional Information (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:AreaOfLand",
"reportCount": 1,
"unique": true,
"unitRef": "U_sqft",
"xsiNil": "false"
}
},
"R29": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100300 - Disclosure - Commitments and Contingencies - Summary of components of the lease expense (Detail)",
"menuCat": "Details",
"order": "29",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfTheLeaseExpenseDetail",
"shortName": "Commitments and Contingencies - Summary of components of the lease expense (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:LeaseCostTableTextBlock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseCost",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R3": {
"firstAnchor": {
"ancestors": [
"us-gaap:CommonStockParOrStatedValuePerShare",
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_UnitedStatesOfAmericaDollarsShare",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100020 - Statement - Condensed Balance Sheets (Parenthetical)",
"menuCat": "Statements",
"order": "3",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"shortName": "Condensed Balance Sheets (Parenthetical)",
"subGroupType": "parenthetical",
"uniqueAnchor": {
"ancestors": [
"us-gaap:CommonStockParOrStatedValuePerShare",
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:CommonStockParOrStatedValuePerShare",
"reportCount": 1,
"unique": true,
"unitRef": "U_UnitedStatesOfAmericaDollarsShare",
"xsiNil": "false"
}
},
"R30": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100310 - Disclosure - Commitments and Contingencies - Summary of supplemental cash flow information related to lease (Detail)",
"menuCat": "Details",
"order": "30",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail",
"shortName": "Commitments and Contingencies - Summary of supplemental cash flow information related to lease (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeasePayments",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R31": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"hcwb:SupplementalBalanceSheetOperatingLeasesDisclosureTableTextblock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:OperatingLeaseRightOfUseAsset",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100320 - Disclosure - Commitments and Contingencies - Supplemental balance sheet information related to lease (Detail)",
"menuCat": "Details",
"order": "31",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail",
"shortName": "Commitments and Contingencies - Supplemental balance sheet information related to lease (Detail)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"hcwb:SupplementalBalanceSheetOperatingLeasesDisclosureTableTextblock",
"div",
"us-gaap:CommitmentsDisclosureTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_edf8b07d-1c81-49e9-bddb-354094289080",
"decimals": "0",
"lang": null,
"name": "us-gaap:OperatingLeaseLiability",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R32": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:SubsequentEventsTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_7b5c5213-a5bf-46a5-9234-5acc5a827863",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100340 - Disclosure - Subsequent Events - Additional Information (Details)",
"menuCat": "Details",
"order": "32",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"shortName": "Subsequent Events - Additional Information (Details)",
"subGroupType": "details",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"us-gaap:SubsequentEventsTextBlock",
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_7b5c5213-a5bf-46a5-9234-5acc5a827863",
"decimals": "-5",
"first": true,
"lang": null,
"name": "us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R4": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100030 - Statement - Condensed Statements of Operations (Unaudited)",
"menuCat": "Statements",
"order": "4",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited",
"shortName": "Condensed Statements of Operations (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"lang": null,
"name": "us-gaap:CostOfRevenue",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R5": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_e4372d2c-916b-4bcd-bdf3-4d17c717b9ea",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100040 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
"menuCat": "Statements",
"order": "5",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited",
"shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_e4372d2c-916b-4bcd-bdf3-4d17c717b9ea",
"decimals": "INF",
"first": true,
"lang": null,
"name": "us-gaap:SharesOutstanding",
"reportCount": 1,
"unique": true,
"unitRef": "U_shares",
"xsiNil": "false"
}
},
"R6": {
"firstAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"first": true,
"lang": null,
"name": "us-gaap:NetIncomeLoss",
"reportCount": 1,
"unitRef": "U_USD",
"xsiNil": "false"
},
"groupType": "statement",
"isDefault": "false",
"longName": "100050 - Statement - Condensed Statements of Cash Flows (Unaudited)",
"menuCat": "Statements",
"order": "6",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"shortName": "Condensed Statements of Cash Flows (Unaudited)",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"span",
"p",
"td",
"tr",
"table",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": "0",
"lang": null,
"name": "us-gaap:DepreciationDepletionAndAmortization",
"reportCount": 1,
"unique": true,
"unitRef": "U_USD",
"xsiNil": "false"
}
},
"R7": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100060 - Disclosure - Organization and Summary of Significant Accounting Policies",
"menuCat": "Notes",
"order": "7",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
"shortName": "Organization and Summary of Significant Accounting Policies",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R8": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100070 - Disclosure - Accrued Liabilities and Other Current Liabilities",
"menuCat": "Notes",
"order": "8",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilities",
"shortName": "Accrued Liabilities and Other Current Liabilities",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
},
"R9": {
"firstAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
},
"groupType": "disclosure",
"isDefault": "false",
"longName": "100080 - Disclosure - Debt, Net",
"menuCat": "Notes",
"order": "9",
"role": "http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNet",
"shortName": "Debt, Net",
"subGroupType": "",
"uniqueAnchor": {
"ancestors": [
"div",
"body",
"html"
],
"baseRef": "hcwb-20230331.htm",
"contextRef": "C_657a480d-3bcf-4fbc-a75e-3a1154b804f6",
"decimals": null,
"first": true,
"lang": "en-US",
"name": "us-gaap:DebtDisclosureTextBlock",
"reportCount": 1,
"unique": true,
"unitRef": null,
"xsiNil": "false"
}
}
},
"segmentCount": 21,
"tag": {
"dei_AmendmentDescription": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Description of changes contained within amended document.",
"label": "Amendment Description"
}
}
},
"localname": "AmendmentDescription",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "stringItemType"
},
"dei_AmendmentFlag": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
"label": "Amendment Flag"
}
}
},
"localname": "AmendmentFlag",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_CityAreaCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area code of city",
"label": "City Area Code"
}
}
},
"localname": "CityAreaCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_CoverAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cover page.",
"label": "Cover [Abstract]"
}
}
},
"localname": "CoverAbstract",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"xbrltype": "stringItemType"
},
"dei_CurrentFiscalYearEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "End date of current fiscal year in the format --MM-DD.",
"label": "Current Fiscal Year End Date"
}
}
},
"localname": "CurrentFiscalYearEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "gMonthDayItemType"
},
"dei_DocumentFiscalPeriodFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
"label": "Document Fiscal Period Focus"
}
}
},
"localname": "DocumentFiscalPeriodFocus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "fiscalPeriodItemType"
},
"dei_DocumentFiscalYearFocus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
"label": "Document Fiscal Year Focus"
}
}
},
"localname": "DocumentFiscalYearFocus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "gYearItemType"
},
"dei_DocumentPeriodEndDate": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.",
"label": "Document Period End Date"
}
}
},
"localname": "DocumentPeriodEndDate",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "dateItemType"
},
"dei_DocumentQuarterlyReport": {
"auth_ref": [
"r447"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as an quarterly report.",
"label": "Document Quarterly Report"
}
}
},
"localname": "DocumentQuarterlyReport",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentTransitionReport": {
"auth_ref": [
"r448"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true only for a form used as a transition report.",
"label": "Document Transition Report"
}
}
},
"localname": "DocumentTransitionReport",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_DocumentType": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
"label": "Document Type"
}
}
},
"localname": "DocumentType",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "submissionTypeItemType"
},
"dei_EntityAddressAddressLine1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 1 such as Attn, Building Name, Street Name",
"label": "Entity Address, Address Line One"
}
}
},
"localname": "EntityAddressAddressLine1",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressAddressLine2": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Address Line 2 such as Street or Suite number",
"label": "Entity Address, Address Line Two"
}
}
},
"localname": "EntityAddressAddressLine2",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressCityOrTown": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the City or Town",
"label": "Entity Address, City or Town"
}
}
},
"localname": "EntityAddressCityOrTown",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressPostalZipCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Code for the postal or zip code",
"label": "Entity Address, Postal Zip Code"
}
}
},
"localname": "EntityAddressPostalZipCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityAddressStateOrProvince": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the state or province.",
"label": "Entity Address, State or Province"
}
}
},
"localname": "EntityAddressStateOrProvince",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "stateOrProvinceItemType"
},
"dei_EntityCentralIndexKey": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
"label": "Entity Central Index Key"
}
}
},
"localname": "EntityCentralIndexKey",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "centralIndexKeyItemType"
},
"dei_EntityCommonStockSharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
"label": "Entity Common Stock, Shares Outstanding"
}
}
},
"localname": "EntityCommonStockSharesOutstanding",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "sharesItemType"
},
"dei_EntityCurrentReportingStatus": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Current Reporting Status"
}
}
},
"localname": "EntityCurrentReportingStatus",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityEmergingGrowthCompany": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if registrant meets the emerging growth company criteria.",
"label": "Entity Emerging Growth Company"
}
}
},
"localname": "EntityEmergingGrowthCompany",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityExTransitionPeriod": {
"auth_ref": [
"r450"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
"label": "Entity Ex Transition Period"
}
}
},
"localname": "EntityExTransitionPeriod",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityFileNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
"label": "Securities Act File Number"
}
}
},
"localname": "EntityFileNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "fileNumberItemType"
},
"dei_EntityFilerCategory": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
"label": "Entity Filer Category"
}
}
},
"localname": "EntityFilerCategory",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "filerCategoryItemType"
},
"dei_EntityIncorporationStateCountryCode": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Two-character EDGAR code representing the state or country of incorporation.",
"label": "Entity Incorporation, State or Country Code"
}
}
},
"localname": "EntityIncorporationStateCountryCode",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "edgarStateCountryItemType"
},
"dei_EntityInteractiveDataCurrent": {
"auth_ref": [
"r449"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
"label": "Entity Interactive Data Current"
}
}
},
"localname": "EntityInteractiveDataCurrent",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "yesNoItemType"
},
"dei_EntityRegistrantName": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
"label": "Entity Registrant Name"
}
}
},
"localname": "EntityRegistrantName",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_EntityShellCompany": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
"label": "Entity Shell Company"
}
}
},
"localname": "EntityShellCompany",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntitySmallBusiness": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
"label": "Entity Small Business"
}
}
},
"localname": "EntitySmallBusiness",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "booleanItemType"
},
"dei_EntityTaxIdentificationNumber": {
"auth_ref": [
"r445"
],
"lang": {
"en-us": {
"role": {
"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
"label": "Entity Tax Identification Number"
}
}
},
"localname": "EntityTaxIdentificationNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "employerIdItemType"
},
"dei_LocalPhoneNumber": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Local phone number for entity.",
"label": "Local Phone Number"
}
}
},
"localname": "LocalPhoneNumber",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "normalizedStringItemType"
},
"dei_Security12bTitle": {
"auth_ref": [
"r444"
],
"lang": {
"en-us": {
"role": {
"documentation": "Title of a 12(b) registered security.",
"label": "Title of 12(b) Security"
}
}
},
"localname": "Security12bTitle",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "securityTitleItemType"
},
"dei_SecurityExchangeName": {
"auth_ref": [
"r446"
],
"lang": {
"en-us": {
"role": {
"documentation": "Name of the Exchange on which a security is registered.",
"label": "Security Exchange Name"
}
}
},
"localname": "SecurityExchangeName",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "edgarExchangeCodeItemType"
},
"dei_TradingSymbol": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Trading symbol of an instrument as listed on an exchange.",
"label": "Trading Symbol"
}
}
},
"localname": "TradingSymbol",
"nsuri": "http://xbrl.sec.gov/dei/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CoverPage"
],
"xbrltype": "tradingSymbolItemType"
},
"hcwb_AccountsPayablesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Accounts payable.",
"label": "Accounts Payables [Member]",
"terseLabel": "Accounts Payables [Member]"
}
}
},
"localname": "AccountsPayablesMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_AccruedExpensesCurrentAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Accrued expenses current.",
"label": "Accrued Expenses Current [Axis]"
}
}
},
"localname": "AccruedExpensesCurrentAxis",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_AccruedExpensesCurrentDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Accrued expenses current.",
"label": "Accrued Expenses Current [Domain]"
}
}
},
"localname": "AccruedExpensesCurrentDomain",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_AccruedExpensesCurrentMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Accrued expenses current.",
"label": "Accrued Expenses Current [Member]"
}
}
},
"localname": "AccruedExpensesCurrentMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_AdditionalShareIssuedInMinorityInterest": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Additional share issued in minority interest.",
"label": "Additional Share Issued in Minority Interest"
}
}
},
"localname": "AdditionalShareIssuedInMinorityInterest",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"hcwb_AgreementAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Agreement axis.",
"label": "Agreement [Axis]",
"terseLabel": "Agreement [Axis]"
}
}
},
"localname": "AgreementAxis",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_AgreementDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Agreement.",
"label": "Agreement [Domain]",
"terseLabel": "Agreement [Domain]"
}
}
},
"localname": "AgreementDomain",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_ClassAConvertibleCommonStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Class A convertible common stock.",
"label": "Class A Convertible Common Stock [Member]",
"terseLabel": "Class A Convertible Common Stock [Member]"
}
}
},
"localname": "ClassAConvertibleCommonStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "domainItemType"
},
"hcwb_ClassBConvertibleCommonStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Class B Convertible Common stock",
"label": "Class B Convertible Common stock [Member]",
"terseLabel": "Class B Convertible Common stock [Member]"
}
}
},
"localname": "ClassBConvertibleCommonStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "domainItemType"
},
"hcwb_ClinicalExpenses": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Clinical expenses.",
"label": "Clinical Expenses",
"terseLabel": "Clinical expenses"
}
}
},
"localname": "ClinicalExpenses",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"hcwb_CogentBankMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Cogent bank",
"label": "Cogent Bank [Member]",
"terseLabel": "Cogent Bank Member"
}
}
},
"localname": "CogentBankMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"hcwb_CommonStockOptionsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Common Stock Options [Member]"
}
}
},
"localname": "CommonStockOptionsMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_CondensedBalanceSheetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Condensed balance sheets.",
"label": "Condensed Balance Sheets [Abstract]"
}
}
},
"localname": "CondensedBalanceSheetsAbstract",
"nsuri": "http://hcwbiologics.com/20230331",
"xbrltype": "stringItemType"
},
"hcwb_CondensedBalanceSheetsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Series A redeemable preferred stock",
"label": "Condensed Balance Sheets [Line Items]",
"terseLabel": "Condensed Balance Sheets [Line Items]"
}
}
},
"localname": "CondensedBalanceSheetsLineItems",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "stringItemType"
},
"hcwb_CondensedBalanceSheetsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Condensed balance sheets.",
"label": "Condensed Balance Sheets [Table]"
}
}
},
"localname": "CondensedBalanceSheetsTable",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "stringItemType"
},
"hcwb_ConversionOfSeriesARedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of series A redeemable preferred stock.",
"label": "Conversion Of Series A Redeemable Preferred Stock [Member]"
}
}
},
"localname": "ConversionOfSeriesARedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_ConversionOfSeriesBRedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of series B redeemable preferred stock.",
"label": "Conversion Of Series B Redeemable Preferred Stock [Member]"
}
}
},
"localname": "ConversionOfSeriesBRedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_ConversionOfSeriesCRedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Conversion of series C redeemable preferred stock.",
"label": "Conversion Of Series C Redeemable Preferred Stock [Member]"
}
}
},
"localname": "ConversionOfSeriesCRedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_CumulativeLossesToConductProductResearchAndDevelopmentInFuture": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Cumulative losses to conduct product research and development in future.",
"label": "Cumulative Losses To Conduct Product Research And Development In Future",
"terseLabel": "Research and development"
}
}
},
"localname": "CumulativeLossesToConductProductResearchAndDevelopmentInFuture",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"hcwb_DeferredOfferingCostsPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Deferred offering costs.",
"label": "Deferred Offering Costs [Policy Text Block]",
"terseLabel": "Deferred Offering Costs"
}
}
},
"localname": "DeferredOfferingCostsPolicyTextBlock",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"hcwb_DenominatorAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Denominator [Abstract]",
"terseLabel": "Denominator:"
}
}
},
"localname": "DenominatorAbstract",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_InvestmentImpairmentCharges": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Investment impairment charges.",
"label": "Investment Impairment Charges",
"terseLabel": "Investment impairment charges"
}
}
},
"localname": "InvestmentImpairmentCharges",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"hcwb_LeaseCashFlowAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Lease, Cash Flow [Abstract].",
"label": "Lease Cash Flow Abstract",
"terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
}
}
},
"localname": "LeaseCashFlowAbstract",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_ManufacturingFillFinishAndTesting": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Manufacturing fill, finish and testing.",
"label": "Manufacturing Fill, Finish and Testing"
}
}
},
"localname": "ManufacturingFillFinishAndTesting",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "volumeItemType"
},
"hcwb_NumberOfSharesInMinorityInterest": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares in minority interest.",
"label": "Number of Shares in Minority Interest"
}
}
},
"localname": "NumberOfSharesInMinorityInterest",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"hcwb_NumeratorAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Numerator [Abstract]",
"terseLabel": "Numerator:"
}
}
},
"localname": "NumeratorAbstract",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Operating lease liabilities arising from obtaining right of use assets.",
"label": "Operating Lease Liabilities Arising From Obtaining Right Of Use Assets",
"terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets"
}
}
},
"localname": "OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"hcwb_PayablesAndAccrualsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Payables and accruals.",
"label": "Payables And Accruals [Line Items]",
"terseLabel": "Payables And Accruals [Line Items]"
}
}
},
"localname": "PayablesAndAccrualsLineItems",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_PayablesAndAccrualsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Payables and accruals.",
"label": "Payables And Accruals [Table]"
}
}
},
"localname": "PayablesAndAccrualsTable",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_PrepaidExpensesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Prepaid expenses.",
"label": "Prepaid Expenses [Member]",
"terseLabel": "Prepaid Expenses [Member]"
}
}
},
"localname": "PrepaidExpensesMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_PrimeCapitalVenturesLlcMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Prime capital ventures Llc.",
"label": "Prime Capital Ventures Llc [Member]",
"terseLabel": "Prime Capital Ventures LLC [Member]"
}
}
},
"localname": "PrimeCapitalVenturesLlcMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"hcwb_ProceedsFromIssuanceOfPreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Proceeds from issuance of preferred stock [Member]",
"label": "Proceeds from issuance of preferred stock [Member]",
"terseLabel": "Proceeds from issuance of preferred stock [Member]"
}
}
},
"localname": "ProceedsFromIssuanceOfPreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_ProductionRunAndInitiationOfTesting": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Production run and initiation of testing.",
"label": "Production Run and Initiation of Testing"
}
}
},
"localname": "ProductionRunAndInitiationOfTesting",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "volumeItemType"
},
"hcwb_RedeemablePreferredStocksMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Redeemable Preferred Stocks [Member]",
"terseLabel": "Redeemable Preferred Stock [Member]"
}
}
},
"localname": "RedeemablePreferredStocksMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_ReductionInTheCarryingAmountOfRightOfUseAsset": {
"auth_ref": [],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 4.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Reduction in the carrying amount of right of use asset",
"label": "Reduction in the carrying amount of right of use asset",
"negatedLabel": "Reduction in the carrying amount of right-of-use asset",
"terseLabel": "Reduction in the carrying amount of right of use asset"
}
}
},
"localname": "ReductionInTheCarryingAmountOfRightOfUseAsset",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"hcwb_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Right of use assets obtained in exchange for lease obligations.",
"label": "Right Of Use Assets Obtained In Exchange For Lease Obligations Abstract",
"terseLabel": "Right-of-use assets obtained in exchange for lease obligations:"
}
}
},
"localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail"
],
"xbrltype": "stringItemType"
},
"hcwb_SeriesARedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Series A redeemable preferred stock.",
"label": "Series A Redeemable preferred stock [Member]",
"terseLabel": "Series A Redeemable preferred stock [Member]"
}
}
},
"localname": "SeriesARedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_SeriesBRedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Series B redeemable preferred stock.",
"label": "Series B Redeemable preferred stock [Member]",
"terseLabel": "Series B Redeemable preferred stock [Member]"
}
}
},
"localname": "SeriesBRedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_SeriesCRedeemablePreferredStockMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Series C redeemable preferred stock.",
"label": "Series C Redeemable preferred stock [Member]",
"terseLabel": "Series C Redeemable preferred stock [Member]"
}
}
},
"localname": "SeriesCRedeemablePreferredStockMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"hcwb_SupplementalBalanceSheetOperatingLeasesDisclosureTableTextblock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Supplemental balance sheet operating leases disclosure Table TextBlock.",
"label": "Supplemental Balance Sheet Operating Leases Disclosure [Table TextBlock]",
"terseLabel": "Supplemental balance sheet information related to lease"
}
}
},
"localname": "SupplementalBalanceSheetOperatingLeasesDisclosureTableTextblock",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"hcwb_TreasuryBillsMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Treasury bills member.",
"label": "Treasury Bills [Member]",
"terseLabel": "Treasury bills [Member]"
}
}
},
"localname": "TreasuryBillsMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_TreasuryNotesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Treasury notes member.",
"label": "Treasury Notes [Member]",
"terseLabel": "Treasury notes [Member]"
}
}
},
"localname": "TreasuryNotesMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_USGovernmentBackedSecuritiesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "U.S. Government Backed Securities [Member]",
"label": "U.S. Government Backed Securities [Member]",
"terseLabel": "U.S. Government Backed Securities [Member]"
}
}
},
"localname": "USGovernmentBackedSecuritiesMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_USGovernmentsecuritiesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "U.S.government securities [member]",
"label": "U.S.GovernmentSecurities[member]"
}
}
},
"localname": "USGovernmentsecuritiesMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"hcwb_WugenLicenseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Wugen License.",
"label": "Wugen License [Member]"
}
}
},
"localname": "WugenLicenseMember",
"nsuri": "http://hcwbiologics.com/20230331",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_ConsolidatedEntitiesAxis": {
"auth_ref": [
"r134",
"r251",
"r252",
"r253",
"r254",
"r287",
"r415",
"r474",
"r477",
"r478"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Axis]",
"terseLabel": "Consolidated Entities [Axis]"
}
}
},
"localname": "ConsolidatedEntitiesAxis",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_ConsolidatedEntitiesDomain": {
"auth_ref": [
"r134",
"r251",
"r252",
"r253",
"r254",
"r287",
"r415",
"r474",
"r477",
"r478"
],
"lang": {
"en-us": {
"role": {
"label": "Consolidated Entities [Domain]",
"terseLabel": "Consolidated Entities [Domain]"
}
}
},
"localname": "ConsolidatedEntitiesDomain",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_DirectorMember": {
"auth_ref": [
"r471",
"r498"
],
"lang": {
"en-us": {
"role": {
"label": "Director [Member]",
"terseLabel": "Board of Directors [Member]"
}
}
},
"localname": "DirectorMember",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"srt_TitleOfIndividualAxis": {
"auth_ref": [
"r471",
"r489"
],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Axis]",
"terseLabel": "Title of Individual [Axis]"
}
}
},
"localname": "TitleOfIndividualAxis",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"srt_TitleOfIndividualWithRelationshipToEntityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Title of Individual [Domain]",
"terseLabel": "Title of Individual [Domain]"
}
}
},
"localname": "TitleOfIndividualWithRelationshipToEntityDomain",
"nsuri": "http://fasb.org/srt/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountingPoliciesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Accounting Policies [Abstract]"
}
}
},
"localname": "AccountingPoliciesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
"auth_ref": [
"r16"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
"label": "Accounts Payable and Accrued Liabilities, Current",
"terseLabel": "Accounts Payable and Accrued Liabilities, Current",
"totalLabel": "Accounts Payable and Accrued Liabilities, Current, Total"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
"auth_ref": [
"r14"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
"label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
"terseLabel": "Accrued Liabilities and Other Current Liabilities"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilities"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_AccountsPayableAndAccruedLiabilitiesMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.",
"label": "Accounts Payable and Accrued Liabilities [Member]",
"terseLabel": "Accounts Payable and Accrued Liabilities [Member]"
}
}
},
"localname": "AccountsPayableAndAccruedLiabilitiesMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
"auth_ref": [],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
"label": "Accounts Payable and Other Accrued Liabilities, Current",
"terseLabel": "Accrued liabilities and other current liabilities"
}
}
},
"localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccountsPayableCurrent": {
"auth_ref": [
"r13",
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesCurrent",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accounts Payable, Current",
"terseLabel": "Accounts payable",
"totalLabel": "Accounts Payable, Current, Total"
}
}
},
"localname": "AccountsPayableCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AccruedBonusesCurrent": {
"auth_ref": [
"r18"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Accrued Bonuses, Current",
"terseLabel": "Bonus payable"
}
}
},
"localname": "AccruedBonusesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapital": {
"auth_ref": [
"r61",
"r432",
"r499"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
"label": "Additional Paid in Capital",
"periodEndLabel": "Additional Paid in Capital, Ending Balance",
"periodStartLabel": "Additional Paid in Capital, Beginning Balance",
"terseLabel": "Additional paid-in capital",
"totalLabel": "Additional Paid in Capital, Total"
}
}
},
"localname": "AdditionalPaidInCapital",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AdditionalPaidInCapitalMember": {
"auth_ref": [
"r234",
"r235",
"r236",
"r325",
"r465",
"r466",
"r467",
"r483",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
"label": "Additional Paid-in Capital [Member]"
}
}
},
"localname": "AdditionalPaidInCapitalMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
}
}
},
"localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
"auth_ref": [
"r43",
"r44",
"r232"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
"label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
"terseLabel": "Stock-based compensation , Value",
"totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
}
}
},
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
"auth_ref": [
"r159"
],
"lang": {
"en-us": {
"role": {
"documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
"terseLabel": "Potentially diluted securities"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of antidilutive security.",
"label": "Antidilutive Securities [Axis]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
}
}
},
"localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_AntidilutiveSecuritiesNameDomain": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
"label": "Antidilutive Securities, Name [Domain]"
}
}
},
"localname": "AntidilutiveSecuritiesNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_AreaOfLand": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Area of land held.",
"label": "Area of Land",
"terseLabel": "Area of land"
}
}
},
"localname": "AreaOfLand",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "areaItemType"
},
"us-gaap_Assets": {
"auth_ref": [
"r88",
"r109",
"r132",
"r166",
"r174",
"r178",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r251",
"r253",
"r268",
"r300",
"r363",
"r432",
"r443",
"r475",
"r476",
"r490"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets",
"totalLabel": "Total assets"
}
}
},
"localname": "Assets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets [Abstract]",
"terseLabel": "ASSETS"
}
}
},
"localname": "AssetsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsCurrent": {
"auth_ref": [
"r104",
"r116",
"r132",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r251",
"r253",
"r268",
"r432",
"r475",
"r476",
"r490"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Current",
"totalLabel": "Total current assets"
}
}
},
"localname": "AssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets, Current [Abstract]",
"terseLabel": "Current assets:"
}
}
},
"localname": "AssetsCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_AssetsFairValueDisclosure": {
"auth_ref": [
"r48"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
"label": "Assets, Fair Value Disclosure",
"terseLabel": "Assets",
"totalLabel": "Assets, Fair Value Disclosure, Total"
}
}
},
"localname": "AssetsFairValueDisclosure",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_AssetsFairValueDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Assets, Fair Value Disclosure [Abstract]",
"terseLabel": "Assets:"
}
}
},
"localname": "AssetsFairValueDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location on balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Axis]",
"terseLabel": "Balance Sheet Location [Axis]"
}
}
},
"localname": "BalanceSheetLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_BalanceSheetLocationDomain": {
"auth_ref": [
"r46",
"r47"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the balance sheet (statement of financial position).",
"label": "Balance Sheet Location [Domain]",
"terseLabel": "Balance Sheet Location [Domain]"
}
}
},
"localname": "BalanceSheetLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
"label": "Basis of Accounting, Policy [Policy Text Block]",
"terseLabel": "Basis of Presentation"
}
}
},
"localname": "BasisOfAccountingPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": {
"auth_ref": [
"r75",
"r76"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.",
"label": "Business Description and Accounting Policies [Text Block]",
"verboseLabel": "Organization and Summary of Significant Accounting Policies"
}
}
},
"localname": "BusinessDescriptionAndAccountingPoliciesTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
"auth_ref": [
"r24",
"r25",
"r26"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
"label": "Capital Expenditures Incurred but Not yet Paid",
"terseLabel": "Purchases of property and equipment included in accounts payable and other liabilities"
}
}
},
"localname": "CapitalExpendituresIncurredButNotYetPaid",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAtCarryingValue": {
"auth_ref": [
"r23",
"r106",
"r418"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
"label": "Cash and Cash Equivalents, at Carrying Value",
"periodEndLabel": "Cash and cash equivalents at the end of the period",
"periodStartLabel": "Cash and cash equivalents at the beginning of the period",
"terseLabel": "Cash and cash equivalents",
"totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
}
}
},
"localname": "CashAndCashEquivalentsAtCarryingValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashAndCashEquivalentsAxis": {
"auth_ref": [
"r106"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of cash and cash equivalent balance.",
"label": "Cash and Cash Equivalents [Axis]"
}
}
},
"localname": "CashAndCashEquivalentsAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
"auth_ref": [
"r23",
"r72",
"r130"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
"periodEndLabel": "Cash and cash equivalents at the end of the period",
"periodStartLabel": "Cash and cash equivalents at the beginning of the period",
"totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
"auth_ref": [
"r0",
"r72"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"totalLabel": "Net changes in cash and cash equivalents"
}
}
},
"localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ClassOfStockDomain": {
"auth_ref": [
"r101",
"r111",
"r112",
"r113",
"r132",
"r152",
"r153",
"r156",
"r158",
"r164",
"r165",
"r183",
"r190",
"r192",
"r193",
"r194",
"r197",
"r198",
"r215",
"r216",
"r218",
"r219",
"r222",
"r268",
"r319",
"r320",
"r321",
"r322",
"r325",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r351",
"r372",
"r391",
"r410",
"r411",
"r412",
"r413",
"r414",
"r452",
"r461",
"r468"
],
"lang": {
"en-us": {
"role": {
"documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
"label": "Class of Stock [Domain]"
}
}
},
"localname": "ClassOfStockDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ClassOfStockLineItems": {
"auth_ref": [
"r111",
"r112",
"r113",
"r164",
"r215",
"r216",
"r217",
"r218",
"r219",
"r221",
"r222",
"r319",
"r320",
"r321",
"r322",
"r427",
"r452",
"r461"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Class of Stock [Line Items]"
}
}
},
"localname": "ClassOfStockLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsAndContingencies": {
"auth_ref": [
"r20",
"r54",
"r301",
"r350"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
"label": "Commitments and Contingencies",
"terseLabel": "Commitments and contingencies (Note 8)"
}
}
},
"localname": "CommitmentsAndContingencies",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Commitments and Contingencies Disclosure [Abstract]"
}
}
},
"localname": "CommitmentsAndContingenciesDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_CommitmentsDisclosureTextBlock": {
"auth_ref": [
"r79"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
"label": "Commitments Disclosure [Text Block]",
"terseLabel": "Commitments and Contingencies"
}
}
},
"localname": "CommitmentsDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingencies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_CommonStockMember": {
"auth_ref": [
"r433",
"r434",
"r435",
"r437",
"r438",
"r439",
"r440",
"r465",
"r466",
"r483",
"r496",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Stock that is subordinate to all other stock of the issuer.",
"label": "Common Stock [Member]",
"terseLabel": "Common Stock [Member]"
}
}
},
"localname": "CommonStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_CommonStockParOrStatedValuePerShare": {
"auth_ref": [
"r60"
],
"lang": {
"en-us": {
"role": {
"documentation": "Face amount or stated value per share of common stock.",
"label": "Common Stock, Par or Stated Value Per Share",
"terseLabel": "Common stock public offering price per share",
"verboseLabel": "Common Stock, Par or Stated Value Per Share"
}
}
},
"localname": "CommonStockParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_CommonStockSharesAuthorized": {
"auth_ref": [
"r60",
"r351"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
"label": "Common Stock, Shares Authorized",
"terseLabel": "Common Stock, Shares Authorized"
}
}
},
"localname": "CommonStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockSharesIssued": {
"auth_ref": [
"r60"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
"label": "Common Stock, Shares, Issued",
"terseLabel": "Common Stock, Shares, Issued",
"totalLabel": "Common Stock, Shares, Issued, Total"
}
}
},
"localname": "CommonStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CommonStockValue": {
"auth_ref": [
"r60",
"r302",
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
"label": "Common Stock, Value, Issued",
"periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
"periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
"terseLabel": "Common Stock, Value, Issued",
"totalLabel": "Common Stock, Value, Issued, Total"
}
}
},
"localname": "CommonStockValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConstructionInProgressGross": {
"auth_ref": [
"r78"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
"label": "Construction in Progress, Gross",
"terseLabel": "Construction in progress"
}
}
},
"localname": "ConstructionInProgressGross",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ContractualObligation": {
"auth_ref": [
"r464"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.",
"label": "Contractual Obligation",
"terseLabel": "Future payment obligations",
"totalLabel": "Contractual Obligation, Total"
}
}
},
"localname": "ContractualObligation",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
"auth_ref": [
"r24",
"r25",
"r26"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by description of stock conversions.",
"label": "Stock Conversion Description [Axis]"
}
}
},
"localname": "ConversionOfStockByUniqueDescriptionAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_ConversionOfStockNameDomain": {
"auth_ref": [
"r24",
"r25",
"r26"
],
"lang": {
"en-us": {
"role": {
"documentation": "The unique name of a noncash or part noncash stock conversion.",
"label": "Conversion of Stock, Name [Domain]"
}
}
},
"localname": "ConversionOfStockNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
"auth_ref": [
"r12",
"r38",
"r59",
"r83",
"r220"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
"label": "Convertible Preferred Stock, Shares Issued upon Conversion",
"terseLabel": "Common stock issued to holder of redeemable preferred stock"
}
}
},
"localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_CostOfRevenue": {
"auth_ref": [
"r68",
"r132",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r268",
"r475"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_GrossProfit",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
"label": "Cost of Revenue",
"negatedLabel": "Cost of revenues",
"terseLabel": "Cost of Revenues",
"totalLabel": "Cost of Revenue, Total"
}
}
},
"localname": "CostOfRevenue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_CreditFacilityAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Axis]"
}
}
},
"localname": "CreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_CreditFacilityDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
"label": "Credit Facility [Domain]"
}
}
},
"localname": "CreditFacilityDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_CumulativeDividends": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cumulative cash dividends distributed to shareholders.",
"label": "Cumulative Dividends",
"terseLabel": "Cumulative Dividends"
}
}
},
"localname": "CumulativeDividends",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Debt Disclosure [Abstract]"
}
}
},
"localname": "DebtDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_DebtDisclosureTextBlock": {
"auth_ref": [
"r80",
"r131",
"r199",
"r200",
"r201",
"r202",
"r203",
"r204",
"r205",
"r208",
"r210",
"r211",
"r212"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
"label": "Debt Disclosure [Text Block]",
"terseLabel": "Debt, Net"
}
}
},
"localname": "DebtDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNet"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_DebtInstrumentCarryingAmount": {
"auth_ref": [
"r11",
"r90",
"r213"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
"label": "Long-Term Debt, Gross",
"totalLabel": "Total Debt"
}
}
},
"localname": "DebtInstrumentCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DebtInstrumentMaturityDate": {
"auth_ref": [
"r100",
"r424",
"r484"
],
"lang": {
"en-us": {
"role": {
"documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
"label": "Debt Instrument, Maturity Date",
"terseLabel": "Maturity Date"
}
}
},
"localname": "DebtInstrumentMaturityDate",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "dateItemType"
},
"us-gaap_DebtInstrumentTerm": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
"label": "Debt Instrument, Term",
"terseLabel": "Debt Instrument, Term"
}
}
},
"localname": "DebtInstrumentTerm",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "durationItemType"
},
"us-gaap_DeferredCosts": {
"auth_ref": [
"r87",
"r454"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.",
"label": "Deferred Costs, Noncurrent",
"terseLabel": "long-term deferred offering cost",
"totalLabel": "Deferred Costs, Noncurrent, Total"
}
}
},
"localname": "DeferredCosts",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredOfferingCosts": {
"auth_ref": [
"r473"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
"label": "Deferred Offering Costs",
"terseLabel": "Deferred offering costs"
}
}
},
"localname": "DeferredOfferingCosts",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenue": {
"auth_ref": [
"r456"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
"label": "Deferred Revenue",
"terseLabel": "Deferred Revenue",
"totalLabel": "Deferred Revenue, Total"
}
}
},
"localname": "DeferredRevenue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DeferredRevenueCurrent": {
"auth_ref": [
"r455"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
"label": "Deferred Revenue, Current",
"terseLabel": "Deferred Revenue, Current",
"totalLabel": "Deferred Revenue, Current, Total"
}
}
},
"localname": "DeferredRevenueCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepositsMoneyMarketDeposits": {
"auth_ref": [
"r52"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of deposits in accounts that offer many of the same services as checking accounts although transactions may be somewhat more limited, share some of the characteristics of a money market fund and are insured by the Federal government, also known as money market accounts.",
"label": "Deposits, Money Market Deposits",
"terseLabel": "Federal money market fund"
}
}
},
"localname": "DepositsMoneyMarketDeposits",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DepreciationDepletionAndAmortization": {
"auth_ref": [
"r4",
"r170"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
"label": "Depreciation, Depletion and Amortization",
"terseLabel": "Depreciation and amortization",
"totalLabel": "Depreciation, Depletion and Amortization, Total"
}
}
},
"localname": "DepreciationDepletionAndAmortization",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_Dividends": {
"auth_ref": [
"r2",
"r85"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
"label": "Dividends",
"terseLabel": "Dividends Paid",
"totalLabel": "Dividends, Total",
"verboseLabel": "Dividends"
}
}
},
"localname": "Dividends",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DividendsPayableCurrentAndNoncurrent": {
"auth_ref": [
"r56",
"r57",
"r89",
"r441",
"r494"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
"label": "Dividends Payable",
"terseLabel": "Accrued dividends"
}
}
},
"localname": "DividendsPayableCurrentAndNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_DividendsPreferredStock": {
"auth_ref": [
"r2",
"r85"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
"label": "Dividends, Preferred Stock",
"negatedLabel": "6% cumulative dividends on redeemable preferred stock , Value",
"totalLabel": "Dividends, Preferred Stock, Total"
}
}
},
"localname": "DividendsPreferredStock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EarningsPerShareAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Earnings Per Share [Abstract]"
}
}
},
"localname": "EarningsPerShareAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_EarningsPerShareBasic": {
"auth_ref": [
"r124",
"r140",
"r141",
"r142",
"r143",
"r144",
"r149",
"r152",
"r156",
"r157",
"r158",
"r162",
"r262",
"r263",
"r295",
"r307",
"r421"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
"label": "Earnings Per Share, Basic",
"terseLabel": "Net loss per share, basic",
"totalLabel": "Earnings Per Share, Basic, Total"
}
}
},
"localname": "EarningsPerShareBasic",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerShareDiluted": {
"auth_ref": [
"r124",
"r140",
"r141",
"r142",
"r143",
"r144",
"r152",
"r156",
"r157",
"r158",
"r162",
"r262",
"r263",
"r295",
"r307",
"r421"
],
"lang": {
"en-us": {
"role": {
"documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
"label": "Earnings Per Share, Diluted",
"terseLabel": "Net loss per share, diluted",
"totalLabel": "Earnings Per Share, Diluted, Total"
}
}
},
"localname": "EarningsPerShareDiluted",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "perShareItemType"
},
"us-gaap_EarningsPerSharePolicyTextBlock": {
"auth_ref": [
"r28",
"r29"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
"label": "Earnings Per Share, Policy [Policy Text Block]",
"terseLabel": "Net Loss Per Share"
}
}
},
"localname": "EarningsPerSharePolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EarningsPerShareTextBlock": {
"auth_ref": [
"r148",
"r159",
"r160",
"r161"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for earnings per share.",
"label": "Earnings Per Share [Text Block]",
"terseLabel": "Net Loss Per Share"
}
}
},
"localname": "EarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShare"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
"auth_ref": [
"r240"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Effective Income Tax Rate Reconciliation, Percent",
"terseLabel": "Effective Income Tax Rate Reconciliation, Percent",
"totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total"
}
}
},
"localname": "EffectiveIncomeTaxRateContinuingOperations",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
"auth_ref": [
"r481",
"r482"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
"label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
"terseLabel": "Deferred Tax Assets Valuation Allowance, Percent"
}
}
},
"localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_EmployeeRelatedLiabilitiesCurrent": {
"auth_ref": [
"r18"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
"label": "Employee-related Liabilities, Current",
"terseLabel": "Salaries and Employee Benefits",
"totalLabel": "Employee-related Liabilities, Current, Total"
}
}
},
"localname": "EmployeeRelatedLiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_EquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity [Abstract]"
}
}
},
"localname": "EquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_EquityComponentDomain": {
"auth_ref": [
"r7",
"r102",
"r119",
"r120",
"r121",
"r135",
"r136",
"r137",
"r139",
"r145",
"r147",
"r163",
"r184",
"r185",
"r223",
"r234",
"r235",
"r236",
"r244",
"r245",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r261",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r286",
"r310",
"r311",
"r312",
"r325",
"r391"
],
"lang": {
"en-us": {
"role": {
"documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
"label": "Equity Component [Domain]",
"terseLabel": "Equity Component [Domain]"
}
}
},
"localname": "EquityComponentDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
"auth_ref": [
"r265",
"r266",
"r267"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
"auth_ref": [
"r8"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
"label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
}
}
},
"localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
"auth_ref": [
"r9"
],
"lang": {
"en-us": {
"role": {
"documentation": "Class of asset.",
"label": "Asset Class [Domain]",
"terseLabel": "Asset Class [Domain]"
}
}
},
"localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueByAssetClassAxis": {
"auth_ref": [
"r48",
"r49"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by class of asset.",
"label": "Asset Class [Axis]",
"terseLabel": "Asset Class [Axis]"
}
}
},
"localname": "FairValueByAssetClassAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueByFairValueHierarchyLevelAxis": {
"auth_ref": [
"r207",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r266",
"r291",
"r292",
"r293",
"r425",
"r426",
"r428",
"r429",
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
"label": "Fair Value Hierarchy and NAV [Axis]",
"terseLabel": "Fair Value Hierarchy and NAV [Axis]"
}
}
},
"localname": "FairValueByFairValueHierarchyLevelAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Fair Value Disclosures [Abstract]"
}
}
},
"localname": "FairValueDisclosuresAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_FairValueDisclosuresTextBlock": {
"auth_ref": [
"r264"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
"label": "Fair Value Disclosures [Text Block]",
"terseLabel": "Fair Value of Financial Instruments"
}
}
},
"localname": "FairValueDisclosuresTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstruments"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_FairValueInputsLevel1Member": {
"auth_ref": [
"r207",
"r226",
"r231",
"r266",
"r291",
"r428",
"r429",
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
"label": "Fair Value, Inputs, Level 1 [Member]",
"terseLabel": "Level 1 [Member]"
}
}
},
"localname": "FairValueInputsLevel1Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel2Member": {
"auth_ref": [
"r207",
"r226",
"r231",
"r266",
"r292",
"r425",
"r426",
"r428",
"r429",
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
"label": "Fair Value, Inputs, Level 2 [Member]",
"terseLabel": "Level 2 [Member]"
}
}
},
"localname": "FairValueInputsLevel2Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueInputsLevel3Member": {
"auth_ref": [
"r207",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r266",
"r293",
"r425",
"r426",
"r428",
"r429",
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
"label": "Fair Value, Inputs, Level 3 [Member]",
"terseLabel": "Level 3 [Member]"
}
}
},
"localname": "FairValueInputsLevel3Member",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
"auth_ref": [
"r207",
"r226",
"r227",
"r228",
"r229",
"r230",
"r231",
"r291",
"r292",
"r293",
"r425",
"r426",
"r428",
"r429",
"r430"
],
"lang": {
"en-us": {
"role": {
"documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
"label": "Fair Value Hierarchy and NAV [Domain]",
"terseLabel": "Fair Value Hierarchy and NAV [Domain]"
}
}
},
"localname": "FairValueMeasurementsFairValueHierarchyDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_GeneralAndAdministrativeExpense": {
"auth_ref": [
"r70",
"r374"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "General and Administrative Expense",
"terseLabel": "General and administrative",
"totalLabel": "General and Administrative Expense, Total"
}
}
},
"localname": "GeneralAndAdministrativeExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_GrossProfit": {
"auth_ref": [
"r67",
"r132",
"r166",
"r173",
"r177",
"r179",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r268",
"r423",
"r475"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
"label": "Gross Profit",
"totalLabel": "Net revenues"
}
}
},
"localname": "GrossProfit",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IPOMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "First sale of stock by a private company to the public.",
"label": "IPO [Member]",
"terseLabel": "IPO [Member]"
}
}
},
"localname": "IPOMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeStatementAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Statement [Abstract]"
}
}
},
"localname": "IncomeStatementAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationAxis": {
"auth_ref": [
"r188",
"r189",
"r375"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by location in the income statement.",
"label": "Income Statement Location [Axis]",
"terseLabel": "Income Statement Location [Axis]"
}
}
},
"localname": "IncomeStatementLocationAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncomeStatementLocationDomain": {
"auth_ref": [
"r189",
"r375"
],
"lang": {
"en-us": {
"role": {
"documentation": "Location in the income statement.",
"label": "Income Statement Location [Domain]",
"terseLabel": "Income Statement Location [Domain]"
}
}
},
"localname": "IncomeStatementLocationDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_IncomeTaxDisclosureAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Income Tax Disclosure [Abstract]"
}
}
},
"localname": "IncomeTaxDisclosureAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_IncomeTaxDisclosureTextBlock": {
"auth_ref": [
"r133",
"r238",
"r241",
"r242",
"r243",
"r246",
"r248",
"r249",
"r250",
"r324"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
"label": "Income Tax Disclosure [Text Block]",
"terseLabel": "Income Taxes"
}
}
},
"localname": "IncomeTaxDisclosureTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxes"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_IncomeTaxExpenseBenefit": {
"auth_ref": [
"r98",
"r99",
"r146",
"r147",
"r171",
"r239",
"r247",
"r309"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
"label": "Income Tax Expense (Benefit)",
"terseLabel": "Provision for income taxes",
"totalLabel": "Income Tax Expense (Benefit), Total"
}
}
},
"localname": "IncomeTaxExpenseBenefit",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/IncomeTaxesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
"auth_ref": [
"r3"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 7.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
"label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
"terseLabel": "Accounts payable and other liabilities",
"totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
}
}
},
"localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"auth_ref": [
"r3"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 5.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
"label": "Increase (Decrease) in Accounts Receivable",
"negatedLabel": "Accounts receivable"
}
}
},
"localname": "IncreaseDecreaseInAccountsReceivable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Increase (Decrease) in Operating Capital [Abstract]",
"terseLabel": "Changes in operating assets and liabilities:"
}
}
},
"localname": "IncreaseDecreaseInOperatingCapitalAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
"auth_ref": [
"r453",
"r460"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 8.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in obligation for operating lease.",
"label": "Increase (Decrease) in Operating Lease Liability",
"terseLabel": "Operating lease liability"
}
}
},
"localname": "IncreaseDecreaseInOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"auth_ref": [
"r3"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 6.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
"label": "Increase (Decrease) in Prepaid Expense and Other Assets",
"negatedLabel": "Prepaid expenses and other assets",
"totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
}
}
},
"localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestExpense": {
"auth_ref": [
"r50",
"r95",
"r122",
"r169",
"r276",
"r376",
"r442",
"r500"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
"label": "Interest Expense",
"negatedLabel": "Interest expense",
"totalLabel": "Interest Expense, Total"
}
}
},
"localname": "InterestExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InterestPaidNet": {
"auth_ref": [
"r126",
"r128",
"r129"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
"label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
"terseLabel": "Cash paid for interest"
}
}
},
"localname": "InterestPaidNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_InvestmentOwnedPercentOfNetAssets": {
"auth_ref": [
"r338",
"r340",
"r341",
"r395",
"r399",
"r401",
"r402",
"r405",
"r435",
"r497"
],
"lang": {
"en-us": {
"role": {
"documentation": "Percentage of investment owned to net assets.",
"label": "Investment Owned, Net Assets, Percentage",
"terseLabel": "Investment Owned Percent Of Net Assets"
}
}
},
"localname": "InvestmentOwnedPercentOfNetAssets",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_InvestmentPolicyTextBlock": {
"auth_ref": [
"r308",
"r315",
"r316",
"r317",
"r318",
"r396",
"r397"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for investment in financial asset.",
"label": "Investment, Policy [Policy Text Block]",
"terseLabel": "Investments"
}
}
},
"localname": "InvestmentPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_InvestmentTypeAxis": {
"auth_ref": [
"r337",
"r338",
"r339",
"r340",
"r342",
"r394",
"r395",
"r398",
"r400",
"r401",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r435"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of investments.",
"label": "Investment Type [Axis]"
}
}
},
"localname": "InvestmentTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_InvestmentTypeCategorizationMember": {
"auth_ref": [
"r337",
"r338",
"r339",
"r340",
"r342",
"r394",
"r395",
"r398",
"r400",
"r401",
"r403",
"r404",
"r405",
"r406",
"r407",
"r408",
"r409",
"r435"
],
"lang": {
"en-us": {
"role": {
"documentation": "Asset obtained to generate income or appreciate in value.",
"label": "Investments [Domain]"
}
}
},
"localname": "InvestmentTypeCategorizationMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_Investments": {
"auth_ref": [
"r299"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
"label": "Investments",
"terseLabel": "Investments",
"totalLabel": "Investments, Total"
}
}
},
"localname": "Investments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseAndRentalExpense": {
"auth_ref": [],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
"label": "Operating Leases, Rent Expense",
"terseLabel": "Operating Leases, Rent Expense",
"totalLabel": "Operating Leases, Rent Expense, Total"
}
}
},
"localname": "LeaseAndRentalExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LeaseCostTableTextBlock": {
"auth_ref": [
"r487"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
"label": "Lease, Cost [Table Text Block]",
"terseLabel": "Summary of components of the lease expense"
}
}
},
"localname": "LeaseCostTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LeaseExpirationDate1": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
"label": "Lease Expiration Date",
"terseLabel": "Lease termination date"
}
}
},
"localname": "LeaseExpirationDate1",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "dateItemType"
},
"us-gaap_LegalFees": {
"auth_ref": [
"r69"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
"label": "Legal Fees",
"terseLabel": "Legal Fees"
}
}
},
"localname": "LegalFees",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeLeasesPolicyTextBlock": {
"auth_ref": [
"r280"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
"label": "Lessee, Leases [Policy Text Block]",
"terseLabel": "Operating Leases"
}
}
},
"localname": "LesseeLeasesPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
"auth_ref": [
"r285"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail": {
"order": 2.0,
"parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
"terseLabel": "2024"
}
}
},
"localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LesseeOperatingLeaseTermOfContract": {
"auth_ref": [
"r486"
],
"lang": {
"en-us": {
"role": {
"documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
"label": "Lessee, Operating Lease, Term of Contract",
"terseLabel": "Lease term"
}
}
},
"localname": "LesseeOperatingLeaseTermOfContract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "durationItemType"
},
"us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
"auth_ref": [
"r488"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.",
"label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]",
"terseLabel": "Schedule of remaining lease payments"
}
}
},
"localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Liabilities": {
"auth_ref": [
"r17",
"r132",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r252",
"r253",
"r254",
"r268",
"r349",
"r422",
"r443",
"r475",
"r490",
"r491"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
"label": "Liabilities",
"totalLabel": "Total Liabilities"
}
}
},
"localname": "Liabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities [Abstract]",
"terseLabel": "Liabilities"
}
}
},
"localname": "LiabilitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LiabilitiesAndStockholdersEquity": {
"auth_ref": [
"r65",
"r91",
"r304",
"r432",
"r463",
"r472",
"r485"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
"label": "Liabilities and Equity",
"totalLabel": "Total liabilities and stockholders' equity"
}
}
},
"localname": "LiabilitiesAndStockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrent": {
"auth_ref": [
"r19",
"r105",
"r132",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r252",
"r253",
"r254",
"r268",
"r432",
"r475",
"r490",
"r491"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
"label": "Liabilities, Current",
"totalLabel": "Total current liabilities"
}
}
},
"localname": "LiabilitiesCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LiabilitiesCurrentAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:"
}
}
},
"localname": "LiabilitiesCurrentAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityAxis": {
"auth_ref": [
"r15",
"r462"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
"label": "Lender Name [Axis]"
}
}
},
"localname": "LineOfCreditFacilityAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityFrequencyOfPayments": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of the frequency of periodic payments, which may be presented in a variety of ways (for example, monthly, quarterly, annually).",
"label": "Line of Credit Facility, Frequency of Payments",
"terseLabel": "Line Of Credit Facility Frequency Of Payments"
}
}
},
"localname": "LineOfCreditFacilityFrequencyOfPayments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
"auth_ref": [
"r15"
],
"lang": {
"en-us": {
"role": {
"documentation": "The effective interest rate during the reporting period.",
"label": "Line of Credit Facility, Interest Rate During Period",
"terseLabel": "Credit Facility Interest Rate During Period"
}
}
},
"localname": "LineOfCreditFacilityInterestRateDuringPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "percentItemType"
},
"us-gaap_LineOfCreditFacilityLenderDomain": {
"auth_ref": [
"r15",
"r462"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
"label": "Line of Credit Facility, Lender [Domain]"
}
}
},
"localname": "LineOfCreditFacilityLenderDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_LineOfCreditFacilityLineItems": {
"auth_ref": [
"r462"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Line of Credit Facility [Line Items]"
}
}
},
"localname": "LineOfCreditFacilityLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum amount borrowed under the credit facility at any time during the period.",
"label": "Line of Credit Facility, Maximum Amount Outstanding During Period",
"terseLabel": "Gross Principal Outstanding"
}
}
},
"localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
"auth_ref": [
"r15"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
"label": "Line of Credit Facility, Maximum Borrowing Capacity",
"terseLabel": "Gross Proceeds"
}
}
},
"localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LineOfCreditFacilityTable": {
"auth_ref": [
"r15",
"r462"
],
"lang": {
"en-us": {
"role": {
"documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
"label": "Line of Credit Facility [Table]"
}
}
},
"localname": "LineOfCreditFacilityTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_LongTermDebt": {
"auth_ref": [
"r11",
"r90",
"r206",
"r214",
"r425",
"r426",
"r495"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
"label": "Long-Term Debt",
"terseLabel": "Debt",
"totalLabel": "Long-Term Debt, Total",
"verboseLabel": "Debt, net"
}
}
},
"localname": "LongTermDebt",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtCurrent": {
"auth_ref": [
"r110"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.",
"label": "Long-Term Debt, Current Maturities",
"terseLabel": "Current portion of long term debt",
"totalLabel": "Long-Term Debt, Current Maturities, Total"
}
}
},
"localname": "LongTermDebtCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetAdditionalInformationDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
"auth_ref": [
"r6",
"r134",
"r209"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": 3.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year One",
"terseLabel": "2023"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
"auth_ref": [
"r6",
"r134",
"r209"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": 2.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Five",
"terseLabel": "2027"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
"auth_ref": [
"r6",
"r134",
"r209"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": 0.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Four",
"terseLabel": "2026"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
"auth_ref": [
"r6",
"r134",
"r209"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": 4.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Three",
"terseLabel": "2025"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
"auth_ref": [
"r6",
"r134",
"r209"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails": {
"order": 1.0,
"parentTag": "us-gaap_DebtInstrumentCarryingAmount",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
"label": "Long-Term Debt, Maturity, Year Two",
"terseLabel": "2024"
}
}
},
"localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetScheduleOfMaturitiesOfLongtermDebtDetails"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_LongTermInvestments": {
"auth_ref": [
"r107"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
"label": "Long-Term Investments",
"terseLabel": "Investments",
"totalLabel": "Long-term Investments, Total"
}
}
},
"localname": "LongTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_MoneyMarketFundsMember": {
"auth_ref": [
"r480"
],
"lang": {
"en-us": {
"role": {
"documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
"label": "Money Market Funds [Member]",
"terseLabel": "Money Market Funds [Member]"
}
}
},
"localname": "MoneyMarketFundsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"auth_ref": [
"r127"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
"label": "Net Cash Provided by (Used in) Financing Activities",
"totalLabel": "Net cash provided by financing activities"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
"terseLabel": "Cash flows from financing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"auth_ref": [
"r127"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
"label": "Net Cash Provided by (Used in) Investing Activities",
"totalLabel": "Net cash (used in) provided by investing activities"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
"terseLabel": "Cash flows from investing activities:"
}
}
},
"localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"auth_ref": [
"r72",
"r73",
"r74"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
"weight": 1.0
}
},
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
"label": "Net Cash Provided by (Used in) Operating Activities",
"totalLabel": "Net cash used in operating activities"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
"terseLabel": "Cash flows from operating activities:"
}
}
},
"localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NetIncomeLoss": {
"auth_ref": [
"r66",
"r74",
"r94",
"r103",
"r117",
"r118",
"r121",
"r132",
"r138",
"r140",
"r141",
"r142",
"r143",
"r146",
"r147",
"r154",
"r166",
"r173",
"r177",
"r179",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r263",
"r268",
"r306",
"r371",
"r389",
"r390",
"r423",
"r442",
"r475"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
},
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
"label": "Net Income (Loss)",
"terseLabel": "Net loss",
"totalLabel": "Net loss"
}
}
},
"localname": "NetIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
"auth_ref": [
"r125",
"r140",
"r141",
"r142",
"r143",
"r149",
"r150",
"r155",
"r158",
"r166",
"r173",
"r177",
"r179",
"r423"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
"label": "Net Income (Loss) Available to Common Stockholders, Basic",
"totalLabel": "Net loss available for distribution to common stockholders"
}
}
},
"localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
"label": "New Accounting Pronouncements, Policy [Policy Text Block]",
"terseLabel": "Recently Issued Accounting Pronouncements"
}
}
},
"localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Noncash Investing and Financing Items [Abstract]",
"terseLabel": "Noncash operating, investing and financing activities:"
}
}
},
"localname": "NoncashInvestingAndFinancingItemsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_NoncontrollingInterestMember": {
"auth_ref": [
"r45",
"r223",
"r465",
"r466",
"r467",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
"label": "Noncontrolling Interest [Member]",
"terseLabel": "Minority Interest [Member]"
}
}
},
"localname": "NoncontrollingInterestMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_OperatingExpenses": {
"auth_ref": [],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_OperatingIncomeLoss",
"weight": -1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
"label": "Operating Expenses",
"totalLabel": "Total operating expenses"
}
}
},
"localname": "OperatingExpenses",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingExpensesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Expenses [Abstract]",
"terseLabel": "Operating expenses:"
}
}
},
"localname": "OperatingExpensesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingIncomeLoss": {
"auth_ref": [
"r166",
"r173",
"r177",
"r179",
"r423"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net result for the period of deducting operating expenses from operating revenues.",
"label": "Operating Income (Loss)",
"totalLabel": "Loss from operations"
}
}
},
"localname": "OperatingIncomeLoss",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseCost": {
"auth_ref": [
"r281",
"r431"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
"label": "Operating Lease, Cost",
"terseLabel": "Operating lease cost"
}
}
},
"localname": "OperatingLeaseCost",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfComponentsOfTheLeaseExpenseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiability": {
"auth_ref": [
"r278"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
"label": "Operating Lease, Liability",
"terseLabel": "Operating lease liabilities arising from obtaining right-of-use assets",
"totalLabel": "Total operating lease liabilities"
}
}
},
"localname": "OperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityCurrent": {
"auth_ref": [
"r278"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail": {
"order": 0.0,
"parentTag": "us-gaap_OperatingLeaseLiability",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
"label": "Operating Lease, Liability, Current",
"terseLabel": "short term lease liability",
"verboseLabel": "Operating lease liabilities, current"
}
}
},
"localname": "OperatingLeaseLiabilityCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/AccruedLiabilitiesAndOtherCurrentLiabilitiesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseLiabilityNoncurrent": {
"auth_ref": [
"r278"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail": {
"order": 1.0,
"parentTag": "us-gaap_OperatingLeaseLiability",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
"label": "Operating Lease, Liability, Noncurrent",
"terseLabel": "Operating lease liabilities, net of current portion",
"verboseLabel": "Noncurrent lease liability"
}
}
},
"localname": "OperatingLeaseLiabilityNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasePayments": {
"auth_ref": [
"r279",
"r282"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
"label": "Operating Lease, Payments",
"terseLabel": "Operating cash flows"
}
}
},
"localname": "OperatingLeasePayments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseRightOfUseAsset": {
"auth_ref": [
"r277"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of lessee's right to use underlying asset under operating lease.",
"label": "Operating Lease, Right-of-Use Asset",
"terseLabel": "Operating lease right of use asset",
"verboseLabel": "Operating lease right-of-use assets"
}
}
},
"localname": "OperatingLeaseRightOfUseAsset",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSupplementalBalanceSheetInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
"auth_ref": [
"r284",
"r431"
],
"lang": {
"en-us": {
"role": {
"documentation": "Weighted average discount rate for operating lease calculated at point in time.",
"label": "Operating Lease, Weighted Average Discount Rate, Percent",
"terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
}
}
},
"localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "percentItemType"
},
"us-gaap_OperatingLeasedAssetsLineItems": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Operating Leased Assets [Line Items]",
"terseLabel": "Operating Leased Assets [Line Items]"
}
}
},
"localname": "OperatingLeasedAssetsLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
"auth_ref": [
"r96",
"r97"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail": {
"order": null,
"parentTag": null,
"root": true,
"weight": null
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
"label": "Operating Leases, Future Minimum Payments Due",
"totalLabel": "Total future minimum lease payments"
}
}
},
"localname": "OperatingLeasesFutureMinimumPaymentsDue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
}
}
},
"localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
"auth_ref": [
"r96",
"r97"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail": {
"order": 1.0,
"parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
"label": "Operating Leases, Future Minimum Payments Due, Next 12 Months",
"terseLabel": "2023"
}
}
},
"localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesSummaryOfTheFutureMinimumPaymentsForTheLeaseAndSubleaseAgreementsDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
}
}
},
"localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_OtherAssetsCurrent": {
"auth_ref": [
"r115",
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 4.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of current assets classified as other.",
"label": "Other Assets, Current",
"terseLabel": "Other current assets"
}
}
},
"localname": "OtherAssetsCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherAssetsNoncurrent": {
"auth_ref": [
"r108"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncurrent assets classified as other.",
"label": "Other Assets, Noncurrent",
"terseLabel": "Other assets",
"totalLabel": "Other Assets, Noncurrent, Total"
}
}
},
"localname": "OtherAssetsNoncurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherLiabilities": {
"auth_ref": [
"r53",
"r298",
"r345",
"r346",
"r443",
"r498"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 0.0,
"parentTag": "us-gaap_Liabilities",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of liabilities classified as other.",
"label": "Other Liabilities",
"totalLabel": "Other Liabilities, Total"
}
}
},
"localname": "OtherLiabilities",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_OtherOperatingIncomeExpenseNet": {
"auth_ref": [],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetIncomeLoss",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
"label": "Other Operating Income (Expense), Net",
"terseLabel": "Other (expense) income, net"
}
}
},
"localname": "OtherOperatingIncomeExpenseNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PayablesAndAccrualsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Payables and Accruals [Abstract]"
}
}
},
"localname": "PayablesAndAccrualsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
"auth_ref": [
"r71"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
"label": "Payments to Acquire Property, Plant, and Equipment",
"negatedLabel": "Purchases of property and equipment",
"totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
}
}
},
"localname": "PaymentsToAcquirePropertyPlantAndEquipment",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockAmountOfPreferredDividendsInArrears": {
"auth_ref": [
"r41"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Aggregate amount of cumulative preferred dividends in arrears.",
"label": "Preferred Stock, Amount of Preferred Dividends in Arrears",
"terseLabel": "Cumulative dividends on redeemable preferred stock , Value"
}
}
},
"localname": "PreferredStockAmountOfPreferredDividendsInArrears",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockDividendsAndOtherAdjustments": {
"auth_ref": [
"r27",
"r451",
"r470"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.",
"label": "Preferred Stock Dividends and Other Adjustments",
"negatedLabel": "Less: cumulative preferred dividends earned in the period",
"negatedTerseLabel": "6% cumulative dividends on redeemable preferred stock , Value",
"totalLabel": "Preferred Stock Dividends and Other Adjustments, Total"
}
}
},
"localname": "PreferredStockDividendsAndOtherAdjustments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PreferredStockMember": {
"auth_ref": [
"r433",
"r434",
"r437",
"r438",
"r439",
"r440",
"r496",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
"label": "Preferred Stock [Member]",
"terseLabel": "Preferred Stock"
}
}
},
"localname": "PreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_PreferredStockSharesAuthorized": {
"auth_ref": [
"r59",
"r351"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
"label": "Preferred Stock, Shares Authorized",
"terseLabel": "Preferred Stock, Shares Authorized"
}
}
},
"localname": "PreferredStockSharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockSharesIssued": {
"auth_ref": [
"r59",
"r215"
],
"lang": {
"en-us": {
"role": {
"documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
"label": "Preferred Stock, Shares Issued",
"terseLabel": "Preferred Stock, Shares Issued",
"totalLabel": "Preferred Stock, Shares Issued, Total"
}
}
},
"localname": "PreferredStockSharesIssued",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_PreferredStockTextBlock": {
"auth_ref": [
"r81"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
"label": "Preferred Stock [Text Block]",
"terseLabel": "Preferred Stock"
}
}
},
"localname": "PreferredStockTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStock"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_PrepaidExpenseCurrent": {
"auth_ref": [
"r114",
"r186",
"r187",
"r419"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 3.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
"label": "Prepaid Expense, Current",
"terseLabel": "Prepaid expenses",
"totalLabel": "Prepaid Expense, Current, Total"
}
}
},
"localname": "PrepaidExpenseCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
"auth_ref": [
"r1"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
"label": "Proceeds from Issuance Initial Public Offering",
"terseLabel": "Proceeds from initial public offering"
}
}
},
"localname": "ProceedsFromIssuanceInitialPublicOffering",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromIssuanceOfCommonStock": {
"auth_ref": [
"r1"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from the additional capital contribution to the entity.",
"label": "Proceeds from Issuance of Common Stock",
"terseLabel": "Proceeds from issuance of common stock"
}
}
},
"localname": "ProceedsFromIssuanceOfCommonStock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ProceedsFromSaleOfShortTermInvestments": {
"auth_ref": [
"r22"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 1.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
"label": "Proceeds from Sale of Short-Term Investments",
"terseLabel": "Proceeds for sale or maturities of short-term investments"
}
}
},
"localname": "ProceedsFromSaleOfShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PropertyPlantAndEquipmentNet": {
"auth_ref": [
"r5",
"r297",
"r305",
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_Assets",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
"label": "Property, Plant and Equipment, Net",
"periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
"periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
"terseLabel": "Property, plant and equipment, net",
"totalLabel": "Property, Plant and Equipment, Net, Total"
}
}
},
"localname": "PropertyPlantAndEquipmentNet",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_PurchaseObligation": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
"label": "Purchase Obligation",
"terseLabel": "Purchase commitment made",
"totalLabel": "Purchase Obligation, Total"
}
}
},
"localname": "PurchaseObligation",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ReceivablesNetCurrent": {
"auth_ref": [
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
"label": "Receivables, Net, Current",
"terseLabel": "Accounts receivable, net",
"totalLabel": "Receivables, Net, Current, Total"
}
}
},
"localname": "ReceivablesNetCurrent",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RedeemableNoncontrollingInterestEquityPreferredCarryingAmount": {
"auth_ref": [
"r32",
"r33",
"r34",
"r35"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of preferred shares (regardless of class), preferred partnership units (regardless of class), preferential membership interests, or any other form of preferred equity regardless of investee entity legal form.",
"label": "Redeemable Noncontrolling Interest, Equity, Preferred, Carrying Amount",
"terseLabel": "Total redeemable preferred stock"
}
}
},
"localname": "RedeemableNoncontrollingInterestEquityPreferredCarryingAmount",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpense": {
"auth_ref": [
"r55",
"r237",
"r492"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_OperatingExpenses",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
"label": "Research and Development Expense",
"terseLabel": "Research and development",
"totalLabel": "Research and Development Expense, Total"
}
}
},
"localname": "ResearchAndDevelopmentExpense",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ResearchAndDevelopmentExpenseMember": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
"label": "Research and Development Expense [Member]",
"terseLabel": "Research and Development Expense [Member]"
}
}
},
"localname": "ResearchAndDevelopmentExpenseMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
"auth_ref": [
"r106"
],
"lang": {
"en-us": {
"role": {
"documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
"label": "Cash and Cash Equivalents [Domain]"
}
}
},
"localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_RetainedEarningsAccumulatedDeficit": {
"auth_ref": [
"r62",
"r85",
"r303",
"r313",
"r314",
"r323",
"r352",
"r432"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 2.0,
"parentTag": "us-gaap_StockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of accumulated undistributed earnings (deficit).",
"label": "Retained Earnings (Accumulated Deficit)",
"periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
"periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
"terseLabel": "Accumulated deficit",
"totalLabel": "Retained Earnings (Accumulated Deficit), Total"
}
}
},
"localname": "RetainedEarningsAccumulatedDeficit",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RetainedEarningsMember": {
"auth_ref": [
"r102",
"r135",
"r136",
"r137",
"r139",
"r145",
"r147",
"r184",
"r185",
"r234",
"r235",
"r236",
"r244",
"r245",
"r255",
"r257",
"r258",
"r260",
"r261",
"r310",
"r312",
"r325",
"r501"
],
"lang": {
"en-us": {
"role": {
"documentation": "Accumulated undistributed earnings (deficit).",
"label": "Retained Earnings [Member]",
"terseLabel": "Accumulated Deficit",
"verboseLabel": "Retained Earnings"
}
}
},
"localname": "RetainedEarningsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"auth_ref": [
"r167",
"r168",
"r172",
"r175",
"r176",
"r180",
"r181",
"r182",
"r224",
"r225",
"r294"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited": {
"order": 0.0,
"parentTag": "us-gaap_GrossProfit",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
"label": "Revenue from Contract with Customer, Including Assessed Tax",
"terseLabel": "Revenues",
"verboseLabel": "Revenue recognized"
}
}
},
"localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenueRecognitionDeferredRevenue": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.",
"label": "Revenue Recognition, Deferred Revenue [Policy Text Block]",
"terseLabel": "Deferred Revenue"
}
}
},
"localname": "RevenueRecognitionDeferredRevenue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_RevenueRecognitionPolicyTextBlock": {
"auth_ref": [
"r373",
"r416",
"r420"
],
"lang": {
"en-us": {
"role": {
"documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
"label": "Revenue [Policy Text Block]",
"terseLabel": "Revenue Recognition"
}
}
},
"localname": "RevenueRecognitionPolicyTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_Revenues": {
"auth_ref": [
"r123",
"r132",
"r167",
"r168",
"r172",
"r175",
"r176",
"r180",
"r181",
"r182",
"r183",
"r190",
"r191",
"r192",
"r193",
"r194",
"r195",
"r196",
"r197",
"r198",
"r268",
"r296",
"r475"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
"label": "Revenues",
"terseLabel": "Net Revenues",
"totalLabel": "Net Revenues"
}
}
},
"localname": "Revenues",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_RevenuesAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Revenues [Abstract]",
"terseLabel": "Revenues:"
}
}
},
"localname": "RevenuesAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
"auth_ref": [
"r283",
"r431"
],
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
"label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
"terseLabel": "Operating lease"
}
}
},
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfSupplementalCashFlowInformationRelatedToLeaseDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SaleOfStockNameOfTransactionDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
"label": "Sale of Stock [Domain]",
"terseLabel": "Sale of Stock [Domain]"
}
}
},
"localname": "SaleOfStockNameOfTransactionDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfOutstandingPotentiallyDilutiveSecuritiesDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
"auth_ref": [
"r28"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
"label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
"terseLabel": "Summary of Outstanding Potentially Dilutive Securities"
}
}
},
"localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
"label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
"terseLabel": "Summary of supplemental cash flow information related to lease"
}
}
},
"localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
"auth_ref": [
"r469"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
"label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
"terseLabel": "Summary of Basic and Diluted Net Income (Loss) Per Common Share"
}
}
},
"localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
"auth_ref": [
"r265",
"r266"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
"label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
"terseLabel": "Summary of assets and liabilities that are measured at fair value on a recurring basis"
}
}
},
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/FairValueOfFinancialInstrumentsTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
"auth_ref": [
"r6"
],
"lang": {
"en-us": {
"role": {
"documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
"label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
"terseLabel": "Schedule of Maturities of Long-term Debt"
}
}
},
"localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureDebtNetTables"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
"label": "Schedule of Operating Leased Assets [Table]"
}
}
},
"localname": "ScheduleOfOperatingLeasedAssetsTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_ScheduleOfStockByClassTable": {
"auth_ref": [
"r31",
"r36",
"r37",
"r38",
"r39",
"r40",
"r42",
"r82",
"r84",
"r85",
"r111",
"r112",
"r113",
"r164",
"r215",
"r216",
"r217",
"r218",
"r219",
"r221",
"r222",
"r319",
"r320",
"r321",
"r322",
"r427",
"r452",
"r461"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
"label": "Schedule of Stock by Class [Table]"
}
}
},
"localname": "ScheduleOfStockByClassTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis": {
"auth_ref": [
"r51"
],
"lang": {
"en-us": {
"role": {
"documentation": "Group of financial instruments held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.",
"label": "Security Owned and Sold, Not yet Purchased, at Fair Value [Axis]"
}
}
},
"localname": "SecurityOwnedAndSoldNotYetPurchasedAtFairValueAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Type of financial instrument held by a broker-dealer for their own account (proprietary securities) for trading or investment purposes that are carried at fair value including securities sold, not yet purchased.",
"label": "Security Owned and Sold, Not yet Purchased Fair Value, Security Name [Domain]"
}
}
},
"localname": "SecurityOwnedAndSoldNotYetPurchasedFairValueSecurityNameDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesAPreferredStockMember": {
"auth_ref": [
"r457",
"r458",
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series A preferred stock.",
"label": "Series A Preferred Stock [Member]"
}
}
},
"localname": "SeriesAPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesBPreferredStockMember": {
"auth_ref": [
"r457",
"r458",
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series B preferred stock.",
"label": "Series B Preferred Stock [Member]"
}
}
},
"localname": "SeriesBPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_SeriesCPreferredStockMember": {
"auth_ref": [
"r457",
"r458",
"r479"
],
"lang": {
"en-us": {
"role": {
"documentation": "Series C preferred stock.",
"label": "Series C Preferred Stock [Member]"
}
}
},
"localname": "SeriesCPreferredStockMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "domainItemType"
},
"us-gaap_ShareBasedCompensation": {
"auth_ref": [
"r3"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 2.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of noncash expense for share-based payment arrangement.",
"label": "Share-Based Payment Arrangement, Noncash Expense",
"terseLabel": "Stock-based compensation",
"totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
}
}
},
"localname": "ShareBasedCompensation",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_SharePrice": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Price of a single share of a number of saleable stocks of a company.",
"label": "Share Price",
"terseLabel": "Share Price",
"verboseLabel": "Price paid for shares"
}
}
},
"localname": "SharePrice",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CommitmentsAndContingenciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "perShareItemType"
},
"us-gaap_SharesOutstanding": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
"label": "Shares, Outstanding",
"periodEndLabel": "Ending balance (in shares)",
"periodStartLabel": "Beginning balance (in shares)"
}
}
},
"localname": "SharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_ShortTermInvestments": {
"auth_ref": [
"r92",
"r93",
"r459"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_AssetsCurrent",
"weight": 1.0
}
},
"crdr": "debit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
"label": "Short-Term Investments",
"terseLabel": "Short-term investments",
"totalLabel": "Short-term Investments, Total"
}
}
},
"localname": "ShortTermInvestments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_ShortTermInvestmentsMember": {
"auth_ref": [
"r407",
"r408",
"r409",
"r417"
],
"lang": {
"en-us": {
"role": {
"documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
"label": "Short-Term Investments [Member]",
"terseLabel": "Short -Term Investment [Member]"
}
}
},
"localname": "ShortTermInvestmentsMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_StatementClassOfStockAxis": {
"auth_ref": [
"r101",
"r111",
"r112",
"r113",
"r132",
"r152",
"r153",
"r156",
"r158",
"r164",
"r165",
"r183",
"r190",
"r192",
"r193",
"r194",
"r197",
"r198",
"r215",
"r216",
"r218",
"r219",
"r222",
"r268",
"r319",
"r320",
"r321",
"r322",
"r325",
"r326",
"r327",
"r328",
"r329",
"r330",
"r331",
"r332",
"r333",
"r334",
"r335",
"r336",
"r351",
"r372",
"r391",
"r410",
"r411",
"r412",
"r413",
"r414",
"r452",
"r461",
"r468"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by the different classes of stock of the entity.",
"label": "Class of Stock [Axis]"
}
}
},
"localname": "StatementClassOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementEquityComponentsAxis": {
"auth_ref": [
"r7",
"r21",
"r102",
"r119",
"r120",
"r121",
"r135",
"r136",
"r137",
"r139",
"r145",
"r147",
"r163",
"r184",
"r185",
"r223",
"r234",
"r235",
"r236",
"r244",
"r245",
"r255",
"r256",
"r257",
"r258",
"r259",
"r260",
"r261",
"r269",
"r270",
"r271",
"r272",
"r273",
"r274",
"r286",
"r310",
"r311",
"r312",
"r325",
"r391"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by component of equity.",
"label": "Equity Components [Axis]",
"terseLabel": "Equity Components [Axis]"
}
}
},
"localname": "StatementEquityComponentsAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementLineItems": {
"auth_ref": [
"r135",
"r136",
"r137",
"r163",
"r294",
"r315",
"r336",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r351",
"r354",
"r355",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r364",
"r365",
"r366",
"r367",
"r368",
"r370",
"r373",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r391",
"r436"
],
"lang": {
"en-us": {
"role": {
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
"label": "Statement [Line Items]"
}
}
},
"localname": "StatementLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfCashFlowsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Cash Flows [Abstract]"
}
}
},
"localname": "StatementOfCashFlowsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfFinancialPositionAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Financial Position [Abstract]"
}
}
},
"localname": "StatementOfFinancialPositionAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementOfStockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Statement of Stockholders' Equity [Abstract]",
"terseLabel": "Redeemable Preferred Stock , Accretion of issuance costs , Value"
}
}
},
"localname": "StatementOfStockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_StatementTable": {
"auth_ref": [
"r135",
"r136",
"r137",
"r163",
"r294",
"r315",
"r336",
"r343",
"r344",
"r345",
"r346",
"r347",
"r348",
"r351",
"r354",
"r355",
"r356",
"r357",
"r358",
"r359",
"r360",
"r361",
"r362",
"r364",
"r365",
"r366",
"r367",
"r368",
"r370",
"r373",
"r374",
"r377",
"r378",
"r379",
"r380",
"r381",
"r382",
"r383",
"r384",
"r385",
"r386",
"r387",
"r388",
"r391",
"r436"
],
"lang": {
"en-us": {
"role": {
"documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
"label": "Statement [Table]",
"terseLabel": "Statement [Table]"
}
}
},
"localname": "StatementTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
"auth_ref": [
"r7",
"r59",
"r60",
"r85",
"r319",
"r391",
"r411"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of new stock issued during the period.",
"label": "Stock Issued During Period, Shares, New Issues",
"terseLabel": "Stock Issued During Period Shares",
"verboseLabel": "Issuance of common stock upon initial public offering, net of issuance cost, Shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesNewIssues",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
"auth_ref": [
"r7",
"r59",
"r60",
"r85",
"r233"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of share options (or share units) exercised during the current period.",
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
"terseLabel": "Issuance of Common Stock upon exercise of stock options, Shares"
}
}
},
"localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
"auth_ref": [
"r7",
"r21",
"r85"
],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of stock issued as a result of the exercise of stock options.",
"label": "Stock Issued During Period, Value, Stock Options Exercised",
"terseLabel": "Issuance of Common Stock upon exercise of stock options , Value"
}
}
},
"localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquity": {
"auth_ref": [
"r60",
"r63",
"r64",
"r77",
"r353",
"r369",
"r392",
"r393",
"r432",
"r443",
"r463",
"r472",
"r485",
"r501"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets": {
"order": 1.0,
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
"label": "Equity, Attributable to Parent",
"periodEndLabel": "Ending balance , Value",
"periodStartLabel": "Beginning balance , Value",
"totalLabel": "Total stockholders' equity"
}
}
},
"localname": "StockholdersEquity",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_StockholdersEquityAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Equity, Attributable to Parent [Abstract]",
"terseLabel": "Stockholders' equity:"
}
}
},
"localname": "StockholdersEquityAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheets"
],
"xbrltype": "stringItemType"
},
"us-gaap_StockholdersEquityReverseStockSplit": {
"auth_ref": [
"r86"
],
"lang": {
"en-us": {
"role": {
"documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
"label": "Stockholders' Equity, Reverse Stock Split",
"terseLabel": "Stockholders' Equity, Reverse Stock Split"
}
}
},
"localname": "StockholdersEquityReverseStockSplit",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventLineItems": {
"auth_ref": [
"r275",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
"label": "Subsequent Event [Line Items]"
}
}
},
"localname": "SubsequentEventLineItems",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventMember": {
"auth_ref": [
"r275",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event [Member]",
"terseLabel": "Subsequent Event [Member]"
}
}
},
"localname": "SubsequentEventMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventTable": {
"auth_ref": [
"r275",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
"label": "Subsequent Event [Table]"
}
}
},
"localname": "SubsequentEventTable",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeAxis": {
"auth_ref": [
"r275",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Axis]"
}
}
},
"localname": "SubsequentEventTypeAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventTypeDomain": {
"auth_ref": [
"r275",
"r289"
],
"lang": {
"en-us": {
"role": {
"documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
"label": "Subsequent Event Type [Domain]"
}
}
},
"localname": "SubsequentEventTypeDomain",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
],
"xbrltype": "domainItemType"
},
"us-gaap_SubsequentEventsAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Subsequent Events [Abstract]"
}
}
},
"localname": "SubsequentEventsAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"xbrltype": "stringItemType"
},
"us-gaap_SubsequentEventsTextBlock": {
"auth_ref": [
"r288",
"r290"
],
"lang": {
"en-us": {
"role": {
"documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
"label": "Subsequent Events [Text Block]",
"terseLabel": "Subsequent Events"
}
}
},
"localname": "SubsequentEventsTextBlock",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/SubsequentEvents"
],
"xbrltype": "textBlockItemType"
},
"us-gaap_SubsidiarySaleOfStockAxis": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"documentation": "Information by type of sale of the entity's stock.",
"label": "Sale of Stock [Axis]",
"terseLabel": "Sale of Stock [Axis]"
}
}
},
"localname": "SubsidiarySaleOfStockAxis",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "stringItemType"
},
"us-gaap_SupplementalCashFlowInformationAbstract": {
"auth_ref": [],
"lang": {
"en-us": {
"role": {
"label": "Supplemental Cash Flow Information [Abstract]",
"terseLabel": "Supplemental disclosure of cash flow information:"
}
}
},
"localname": "SupplementalCashFlowInformationAbstract",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "stringItemType"
},
"us-gaap_TemporaryEquityAccretionToRedemptionValue": {
"auth_ref": [],
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Value of accretion of temporary equity to its redemption value during the period.",
"label": "Temporary Equity, Accretion to Redemption Value",
"terseLabel": "Redeemable Preferred Stock , Accretion of issuance costs , Value"
}
}
},
"localname": "TemporaryEquityAccretionToRedemptionValue",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfChangesInStockholdersEquityUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_TemporaryEquityParOrStatedValuePerShare": {
"auth_ref": [
"r10",
"r30"
],
"lang": {
"en-us": {
"role": {
"documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
"label": "Temporary Equity, Par or Stated Value Per Share",
"terseLabel": "Temporary Equity, Par or Stated Value Per Share"
}
}
},
"localname": "TemporaryEquityParOrStatedValuePerShare",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "perShareItemType"
},
"us-gaap_TemporaryEquitySharesAuthorized": {
"auth_ref": [
"r58"
],
"lang": {
"en-us": {
"role": {
"documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
"label": "Temporary Equity, Shares Authorized",
"terseLabel": "Temporary Equity, Shares Authorized"
}
}
},
"localname": "TemporaryEquitySharesAuthorized",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical"
],
"xbrltype": "sharesItemType"
},
"us-gaap_TemporaryEquitySharesIssued": {
"auth_ref": [
"r58"
],
"lang": {
"en-us": {
"role": {
"documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
"label": "Temporary Equity, Shares Issued",
"terseLabel": "Temporary Equity, Shares Issued"
}
}
},
"localname": "TemporaryEquitySharesIssued",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/CondensedBalanceSheetsParenthetical",
"http://hcwbiologics.com/20230331/taxonomy/role/DisclosurePreferredStockAdditionalInformationDetail"
],
"xbrltype": "sharesItemType"
},
"us-gaap_USTreasuryBillSecuritiesMember": {
"auth_ref": [
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government.",
"label": "US Treasury Bill Securities [Member]",
"terseLabel": "U.S. Treasury bills [Member]"
}
}
},
"localname": "USTreasuryBillSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_USTreasuryNotesSecuritiesMember": {
"auth_ref": [
"r493"
],
"lang": {
"en-us": {
"role": {
"documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
"label": "US Treasury Notes Securities [Member]",
"terseLabel": "US Treasury Notes [Member]"
}
}
},
"localname": "USTreasuryNotesSecuritiesMember",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
],
"xbrltype": "domainItemType"
},
"us-gaap_UnrealizedGainLossOnInvestments": {
"auth_ref": [
"r4"
],
"calculation": {
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited": {
"order": 3.0,
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": -1.0
}
},
"crdr": "credit",
"lang": {
"en-us": {
"role": {
"documentation": "Amount of unrealized gain (loss) on investment.",
"label": "Unrealized Gain (Loss) on Investments",
"negatedLabel": "Unrealized loss on investments, net",
"terseLabel": "Unrealized loss on investments, net",
"totalLabel": "Unrealized Gain (Loss) on Investments, Total"
}
}
},
"localname": "UnrealizedGainLossOnInvestments",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited"
],
"xbrltype": "monetaryItemType"
},
"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
"auth_ref": [
"r151",
"r158"
],
"lang": {
"en-us": {
"role": {
"documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
"label": "Weighted Average Number of Shares Outstanding, Diluted",
"terseLabel": "Weighted average shares outstanding, diluted",
"totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total"
}
}
},
"localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "sharesItemType"
},
"us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
"auth_ref": [
"r149",
"r158"
],
"lang": {
"en-us": {
"role": {
"documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
"label": "Weighted Average Number of Shares Outstanding, Basic",
"terseLabel": "Weighted average shares outstanding, basic",
"totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
}
}
},
"localname": "WeightedAverageNumberOfSharesOutstandingBasic",
"nsuri": "http://fasb.org/us-gaap/2023",
"presentation": [
"http://hcwbiologics.com/20230331/taxonomy/role/NetLossPerShareSummaryOfBasicAndDilutedNetIncomeLossPerCommonShareDetail",
"http://hcwbiologics.com/20230331/taxonomy/role/StatementCondensedStatementsOfOperationsUnaudited"
],
"xbrltype": "sharesItemType"
}
},
"unitCount": 5
}
},
"std_ref": {
"r0": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "230",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r1": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r10": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(27)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r100": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.22(a)(2))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r101": {
"Name": "Regulation S-K (SK)",
"Number": "229",
"Paragraph": "(a)",
"Publisher": "SEC",
"Section": "1402",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r102": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "105",
"URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r103": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "205",
"URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r104": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r105": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r106": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(1))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r107": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(12))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r108": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r109": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(18))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r11": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(22))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r110": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r111": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r112": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r113": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r114": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(7))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r115": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r116": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(9))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r117": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r118": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r119": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r12": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r120": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r121": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r122": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(210.5-03(11))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r123": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(1))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r124": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(25))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r125": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.B)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r126": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r127": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r128": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r129": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r13": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r130": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r131": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(c))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r132": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r133": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h)(2))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r134": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.12-04(a))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r135": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r136": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r137": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r138": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(2)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r139": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)(3)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r14": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(a),20,24)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r140": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r141": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r142": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r143": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r144": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r145": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r146": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r147": {
"Name": "Accounting Standards Codification",
"Paragraph": "9",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r148": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "260",
"URI": "https://asc.fasb.org//260/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r149": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r15": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19(b),22(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r150": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r151": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r152": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r153": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r154": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r155": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r156": {
"Name": "Accounting Standards Codification",
"Paragraph": "60B",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r157": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r158": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r159": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r16": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19,20)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r160": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r161": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r162": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r163": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r164": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r165": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r166": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r167": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r168": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r169": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r17": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.19-26)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r170": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r171": {
"Name": "Accounting Standards Codification",
"Paragraph": "22",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r172": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r173": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r174": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r175": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r176": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r177": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r178": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r179": {
"Name": "Accounting Standards Codification",
"Paragraph": "32",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r18": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.20)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r180": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r181": {
"Name": "Accounting Standards Codification",
"Paragraph": "41",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r182": {
"Name": "Accounting Standards Codification",
"Paragraph": "42",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r183": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r184": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "326",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r185": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(c)(2)",
"Topic": "326",
"URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r186": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "05",
"SubTopic": "10",
"Topic": "340",
"URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r187": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "340",
"URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r188": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r189": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "420",
"URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r19": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.21)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r190": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r191": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r192": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r193": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r194": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r195": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r196": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r197": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r198": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(5))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r199": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r2": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "405",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r20": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.25)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r200": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r201": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(h)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r202": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(i)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r203": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r204": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r205": {
"Name": "Accounting Standards Codification",
"Paragraph": "1C",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r206": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r207": {
"Name": "Accounting Standards Codification",
"Paragraph": "1D",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r208": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r209": {
"Name": "Accounting Standards Codification",
"Paragraph": "1E",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r21": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02.29-31)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r210": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r211": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r212": {
"Name": "Accounting Standards Codification",
"Paragraph": "1I",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r213": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(1)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r214": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)(3)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r215": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r216": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r217": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r218": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(h)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r219": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r22": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r220": {
"Name": "Accounting Standards Codification",
"Paragraph": "16",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r221": {
"Name": "Accounting Standards Codification",
"Paragraph": "18",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r222": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r223": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r224": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r225": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "606",
"URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r226": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r227": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r228": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(A)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r229": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(B)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r23": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r230": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(02)(C)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r231": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(03)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r232": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "35",
"SubTopic": "10",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r233": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)(1)(iv)(02)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r234": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r235": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(1)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r236": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(f)(2)",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r237": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "730",
"URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r238": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "740",
"URI": "https://asc.fasb.org//740/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r239": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r24": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r240": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r241": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r242": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r243": {
"Name": "Accounting Standards Codification",
"Paragraph": "21",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r244": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(2)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r245": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(d)(3)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r246": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r247": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB TOPIC 6.I.7)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r248": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.C)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r249": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "270",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r25": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r250": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r251": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r252": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r253": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bb)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r254": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r255": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(e)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r256": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r257": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(i)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r258": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(iii)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r259": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(h)(1)(iv)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r26": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r260": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "20",
"Subparagraph": "(i)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r261": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r262": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(4)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r263": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r264": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r265": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r266": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r267": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r268": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r269": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r27": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r270": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(a)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r271": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(b)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r272": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(c)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r273": {
"Name": "Accounting Standards Codification",
"Paragraph": "20",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Subparagraph": "(d)",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r274": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r275": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "830",
"URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r276": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r277": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r278": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r279": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(c)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r28": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r280": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r281": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(b)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r282": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r283": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(2)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r284": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(4)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r285": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r286": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "10",
"Subparagraph": "(a)(3)(iii)(03)",
"Topic": "848",
"URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r287": {
"Name": "Accounting Standards Codification",
"Paragraph": "14",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r288": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "855",
"URI": "https://asc.fasb.org//855/tableOfContent",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r289": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "855",
"URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r29": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r290": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "855",
"URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r291": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(1)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r292": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(2)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r293": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(bb)(3)",
"Topic": "860",
"URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r294": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 11.L)",
"Topic": "924",
"URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r295": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(27))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r296": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "235",
"Subparagraph": "(SX 210.9-05(b)(2))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r297": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "360",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r298": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(15))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r299": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(1)(h))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r3": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r30": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r300": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(12))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r301": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(19))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r302": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(22))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r303": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r304": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(25))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r305": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(8))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r306": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(18))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r307": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(23))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r308": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(3)(b))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r309": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.7-04(9))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r31": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(CFRR 211.02)",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r310": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r311": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(1)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r312": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(f)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r313": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(g)(2)(i)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r314": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(h)(2)",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r315": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r316": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(f)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r317": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(f)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r318": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(f)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r319": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r32": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(12)(c)",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r320": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2)(i))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r321": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2)(ii))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r322": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.6-03(i)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r323": {
"Name": "Accounting Standards Codification",
"Paragraph": "11",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r324": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r325": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r326": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r327": {
"Name": "Accounting Standards Codification",
"Paragraph": "27",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r328": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r329": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r33": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(16)(c)",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r330": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r331": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r332": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(e)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r333": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(f)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r334": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(g)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r335": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "205",
"Subparagraph": "(h)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r336": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r337": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(b)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r338": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(c)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r339": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(c)(2)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r34": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "14",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r340": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(a)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r341": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(a)(2)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r342": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r343": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r344": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r345": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r346": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r347": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(13)(a)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r348": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(13)(a)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r349": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(14))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r35": {
"Name": "Accounting Standards Codification",
"Paragraph": "3A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "15",
"Topic": "480",
"URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r350": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(15))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r351": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(16)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r352": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(17))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r353": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(19))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r354": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(2)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r355": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(2)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r356": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r357": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r358": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(3)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r359": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r36": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r360": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r361": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r362": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(6)(e))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r363": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(8))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r364": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r365": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(c))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r366": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r367": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(9)(e))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r368": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-05(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r369": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-05(4))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r37": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r370": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r371": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r372": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "220",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r373": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r374": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r375": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(2)(g)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r376": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r377": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r378": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r379": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r38": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r380": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(5))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r381": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r382": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(a)(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r383": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r384": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r385": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(3))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r386": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(5))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r387": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r388": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(7)(c)(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r389": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-07(9))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r39": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r390": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(1)(d))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r391": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r392": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r393": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r394": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r395": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r396": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(i)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r397": {
"Name": "Accounting Standards Codification",
"Paragraph": "19",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(2)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r398": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r399": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r4": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r40": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r400": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r401": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r402": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column D))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r403": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r404": {
"Name": "Accounting Standards Codification",
"Paragraph": "5D",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r405": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r406": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column A))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r407": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column B))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r408": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column C))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r409": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column D))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r41": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r410": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r411": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r412": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(b)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r413": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(c)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r414": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "505",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r415": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "360",
"Subparagraph": "(SX 210.12-28(Footnote 4))",
"Topic": "970",
"URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r416": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(e)",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r417": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-15(Column A))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r418": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r419": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(g)",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r42": {
"Name": "Accounting Standards Codification",
"Paragraph": "8",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r420": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r421": {
"Name": "Accounting Standards Codification",
"Paragraph": "52",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r422": {
"Name": "Accounting Standards Codification",
"Paragraph": "30",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r423": {
"Name": "Accounting Standards Codification",
"Paragraph": "31",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "280",
"URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r424": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r425": {
"Name": "Accounting Standards Codification",
"Paragraph": "69B",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r426": {
"Name": "Accounting Standards Codification",
"Paragraph": "69C",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r427": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r428": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r429": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(iv)(01)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r43": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r430": {
"Name": "Accounting Standards Codification",
"Paragraph": "17",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r431": {
"Name": "Accounting Standards Codification",
"Paragraph": "53",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r432": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r433": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(b)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r434": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(a)(1)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r435": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "210",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r436": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "310",
"Subparagraph": "(d)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r437": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r438": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r439": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r44": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "20",
"Topic": "718",
"URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r440": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "320",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r441": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "405",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r442": {
"Name": "Accounting Standards Codification",
"Paragraph": "10",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "830",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r443": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "830",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
"role": "http://www.xbrl.org/2003/role/exampleRef"
},
"r444": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r445": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "b-2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r446": {
"Name": "Exchange Act",
"Number": "240",
"Publisher": "SEC",
"Section": "12",
"Subsection": "d1-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r447": {
"Name": "Form 10-Q",
"Number": "240",
"Publisher": "SEC",
"Section": "308",
"Subsection": "a",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r448": {
"Name": "Forms 10-K, 10-Q, 20-F",
"Number": "240",
"Publisher": "SEC",
"Section": "13",
"Subsection": "a-1",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r449": {
"Name": "Regulation S-T",
"Number": "232",
"Publisher": "SEC",
"Section": "405",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r45": {
"Name": "Accounting Standards Codification",
"Paragraph": "15",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "810",
"URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r450": {
"Name": "Securities Act",
"Number": "7A",
"Publisher": "SEC",
"Section": "B",
"Subsection": "2",
"role": "http://www.xbrl.org/2003/role/presentationRef"
},
"r451": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.B)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5",
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
},
"r452": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "272",
"URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
"role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
},
"r453": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(g)(1)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r454": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(17))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r455": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r456": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(26)(c))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r457": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r458": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r459": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(8))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r46": {
"Name": "Accounting Standards Codification",
"Paragraph": "4A",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r460": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r461": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(d))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r462": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(f))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r463": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(g)(1)(ii))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r464": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r465": {
"Name": "Accounting Standards Codification",
"Paragraph": "23",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r466": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r467": {
"Name": "Accounting Standards Codification",
"Paragraph": "5",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "250",
"URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r468": {
"Name": "Accounting Standards Codification",
"Paragraph": "55",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r469": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r47": {
"Name": "Accounting Standards Codification",
"Paragraph": "4B",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(d)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r470": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "260",
"URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r471": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "310",
"URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r472": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "323",
"URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r473": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 5.A)",
"Topic": "340",
"URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r474": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(i))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r475": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r476": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r477": {
"Name": "Accounting Standards Codification",
"Paragraph": "1A",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-01(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r478": {
"Name": "Accounting Standards Codification",
"Paragraph": "1B",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r479": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r48": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r480": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(d)(ii)",
"Topic": "715",
"URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r481": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r482": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 6.I.Fact.4)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r483": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "65",
"SubTopic": "40",
"Subparagraph": "(e)(3)",
"Topic": "815",
"URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r484": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)(2)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r485": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(f)",
"Topic": "825",
"URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r486": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)(3)",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r487": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r488": {
"Name": "Accounting Standards Codification",
"Paragraph": "12",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "30",
"Topic": "842",
"URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r489": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "850",
"URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r49": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r490": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(a)",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r491": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "852",
"URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r492": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "25",
"SubTopic": "730",
"Topic": "912",
"URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r493": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "320",
"Subparagraph": "(b)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r494": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(15)(a))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r495": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
"Topic": "944",
"URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r496": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "205",
"Subparagraph": "(a)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r497": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "210",
"Subparagraph": "(a)(3)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r498": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(12)(b)(1))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r499": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.6-04(18))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r5": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r50": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "30",
"Topic": "835",
"URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r500": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "220",
"Subparagraph": "(i)",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r501": {
"Name": "Accounting Standards Codification",
"Paragraph": "3",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.6-09(4)(b))",
"Topic": "946",
"URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
"role": "http://www.xbrl.org/2009/role/commonPracticeRef"
},
"r51": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "320",
"Topic": "940",
"URI": "https://asc.fasb.org//1943274/2147481961/940-320-45-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r52": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.12)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r53": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.15)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r54": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03.17)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r55": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Topic": "985",
"URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r56": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(20))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r57": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(24))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r58": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(27)(b))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r59": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(28))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r6": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "470",
"URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r60": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(29))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r61": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(1))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r62": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30)(a)(3))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r63": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(30))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r64": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(31))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r65": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-02(32))",
"Topic": "210",
"URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r66": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03(20))",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r67": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.1,2)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r68": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.2)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r69": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.3)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r7": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r70": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.5-03.4)",
"Topic": "220",
"URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r71": {
"Name": "Accounting Standards Codification",
"Paragraph": "13",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r72": {
"Name": "Accounting Standards Codification",
"Paragraph": "24",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r73": {
"Name": "Accounting Standards Codification",
"Paragraph": "25",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r74": {
"Name": "Accounting Standards Codification",
"Paragraph": "28",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "10",
"Topic": "230",
"URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r75": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "235",
"URI": "https://asc.fasb.org//235/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r76": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "275",
"URI": "https://asc.fasb.org//275/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r77": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.E)",
"Topic": "310",
"URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r78": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "360",
"URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r79": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "440",
"URI": "https://asc.fasb.org//440/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r8": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(bbb)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r80": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "470",
"URI": "https://asc.fasb.org//470/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r81": {
"Name": "Accounting Standards Codification",
"Publisher": "FASB",
"Topic": "505",
"URI": "https://asc.fasb.org//505/tableOfContent",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r82": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r83": {
"Name": "Accounting Standards Codification",
"Paragraph": "6",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(b)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r84": {
"Name": "Accounting Standards Codification",
"Paragraph": "7",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r85": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.3-04)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r86": {
"Name": "Accounting Standards Codification",
"Paragraph": "4",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SAB Topic 4.C)",
"Topic": "505",
"URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r87": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(10))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r88": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(11))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r89": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(15)(5))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r9": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "10",
"Subparagraph": "(c)",
"Topic": "820",
"URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r90": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(16))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r91": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(23))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r92": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(4))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r93": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "210",
"Subparagraph": "(SX 210.9-03(5))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r94": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04(22))",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r95": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "220",
"Subparagraph": "(SX 210.9-04.9)",
"Topic": "942",
"URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
"role": "http://fasb.org/us-gaap/role/ref/legacyRef"
},
"r96": {
"Name": "Accounting Standards Codification",
"Paragraph": "40",
"Publisher": "FASB",
"Section": "55",
"SubTopic": "10",
"Subparagraph": "(Note 3)",
"Topic": "840",
"URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40",
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
},
"r97": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "50",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "840",
"URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2",
"role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
},
"r98": {
"Name": "Accounting Standards Codification",
"Paragraph": "2",
"Publisher": "FASB",
"Section": "45",
"SubTopic": "20",
"Subparagraph": "(a)",
"Topic": "740",
"URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
},
"r99": {
"Name": "Accounting Standards Codification",
"Paragraph": "1",
"Publisher": "FASB",
"Section": "S99",
"SubTopic": "10",
"Subparagraph": "(SX 210.4-08(h))",
"Topic": "235",
"URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
"role": "http://www.xbrl.org/2003/role/disclosureRef"
}
},
"version": "2.2"
}
ZIP
50
0000950170-23-041458-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0000950170-23-041458-xbrl.zip
M4$L#!!0 ( #R("E>$80#GL!P! +:@$P 1 :&-W8BTR,#(S,#,S,2YH
M=&WL?6M7',>2[??[*^IR'LM>MQ/E^X%LWX61=,P:6=(1\IPY]XM7/J'&33?N
MJI;$_/J;6=V-0("0H!JRFIPYEA!=7945D1%[1V1DY __]^/QN'KO9TT]G?RX
MA;;A5N4G=NKJR>&/6[L'>_O[6__WIQ_^-P#5LQ?[KZI7_D.U:]OZO7]6-W8\
M;>8S7WUW\.OWU?YD7$]\]5\_OWU9/9O:^;&?M!6HCMKV9.?)DP\?/FR[4$^:
MZ7C>QDFL/CQJJ^_L]U7Z4GSR9.+'X]/J13W1$UOK<76P>N0HCM%N5[OC
M4V?:NIWOK&S]Y[MYUN^;]^.&JC+*(\)LV/6^?&_8%L3V>'3Y!2ZLG'=,W6
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M \38 &@P%FC!/" :(4:-A#3PK9\ 0#AJ_HZ&UV\2V[^Q5@?WFIXU6*"_;@59^1.J#]Z!]K9W&_]]"[^
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MF?G@HS^POOGIAX3-.TT'A?&658?5.PE9?MQJHB,;)USL?G )6&++]
ML7'I<1?OL7C<^6=T_VRF\UGWKXZ+["S?NQ/KWN]("8_3*Y/X=U1A_$GA^-X(
M,F0\X=)BNK7ZJN]F\NI?M4O_#K6?5=T0_)50MK?_'Q?G[>=?7MVN\8=)4XM_
MNOBPCR?CVM;MK_[8Q$>X.GZZX+4K];[0]>P_]7CN?S[=;1K?[HUUT^Q^K)NM
MGY*T=MY%'AHI[>FK:>N;Q6U^>'+EW7]:#>ML$$^N>N.3SL.DPL:N%HAT:?X;G8KF>8Y)AI('R#P)EHN11A[:0>@D+,??XEW
MU#-[=/K2O_?CA78N7;\_.9FW37<%6:NBR(*Q]:$H0K&.KCY$='+18W-(@:'*
M APBOD)I7; L5T7%",W5[0MMZW$4CS(^E #U]A!
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M#H[T+%&5*V]PP0'T\GG3V^/NER76NV0OSU5HC[LT*,8@@J' /<&AD)O>@8
M-P1184%3(I@2KDR">YL$#^.*(<>,2V@ BY8?HU3#@?;(@#C3-"9$!<)"KI.@
M#[:+^H+S+\1"JTM^G4[\Z:]Z]H=O7\PG;C 1$;8"!QVBH^ L93(( I)I#"01
MT/@8K7*",[(K[Y@*"A.F:6,$@6$"AI0H3 P
MRGI H%=1)]P%JG+3RQG[C:ZY8U+/_YRGY%STUM$Z4I[H@LGLNA@FQ2_J\1M=
MN_W)GCZI6SW>2#R65EC.*0,,Q1B*\@C*,:)RP*EH8T(Y(H0NZGQ(@T.$:2<"
M 8Z+Z @Y%4 ;PX!SS$36'! 50\C599H:ZA&Q5)#*">> AIA'12&:0LVTF$$X
MTMH[)]?N&;]YEJ9EQ5X2F)#%N0@54)I80 V30 =J@57]_D.DL?)"^6
M 0VW5FL,?0S(10K("2% *P2!D88:$2RU*-ND$B<:8"K_10('O(:JZYQ6F'FD$H\%HJ1"PC*1XRFB@%)= 6(,%<<91
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MP(AL4WD7286,;E$*J8'SU"E%@G0P6VL/_U. ?[:]/OY2^\4IGKDD?$.
M8&)P]/L?VL4LT)8 8A*>Z&BCP62:@RXEHXR
MQ@/RV9419:N5_F)"%ZRU..J"10"D+A4 (INVIAJHJ""4YY>I>_A:[![-@AAC
M-8S\5!#C(M8% J31'! :'1?3%%N>;=E/;K%#G\LP7[4?-*]EF(=9[$:1E G%
M.)#(HLBCB00&QW\&;J03P:5IG.L$SI%']Q@ "T\-PL@#*%,I$.8B3F*!@-%:
M64F]U&BCZQ!NBD6+H]O[G4G"G9<26.*AHR0_LOQ !" '
M9VL"4H$)$$A@B41'MZN261O+8["C E]_TN+!T@)022T)$L"$5"$=L :*P$A8
M681CI83%,MOEQT=5P^*#1U9! VPDL&EG0MK@J57\"4*MM!$4^EP5M3^QTV-_
M1@RNK@!(K:Z2YG:C*2?-3$\Z$K'81[*12QR.>V'21E$?(K>C4#E@8"I04D%1
MQ1PD)MM<>O8J?:!MV!PA8QP'/G7/H4*JU.F"@^A'O?>01O#/-LN::Y'.>GB\
MDY(8B16P7$) &3*IG H#IDA4HK6J@"@J@I9&1&C&,
M!0R(K;^"\Q9$$/:S4B:\$A92@'PJ7V4Q9M(N(9Z66E".0Y1"KK-T /%*CW1,
M8&69P3#R+T.C/R$,2"T]D$YB:SAT7F7;52:W[:SK2:5J;F(0%3V'MHBEO5/=
M'L0 2#0F#*/"B,LNZS\ #?48]B+!"6%1YY(HDFK@(% 81O(6'7UT^91@/(2Z
M@*S#WN%VJ;54:@Y5)/1*A=1",7(W)2,O0)H)3Q$-^6;8!QOSK7?]I<_"=RB@
M<\0!H5G:0XP],-P%P#@V7#"G9,8E&8O-KJ>O/TR\BRSH8#IV<2;\V[=OYE%7
MNHF_;<^T<\V.V9^U_<.[KV[:FHWB K7:$PL!HJD;>*3[0$E*HVTS*6U$!*N&
MD,K9? L3"A(1& **B(3.J>JP1XC#^HA"UYSH+GHNA=U%$"#8
MI$6QB%8:&@6@,)C80#AWV;8$^%)_E*%GVST5TF,?;^=4='T>:U8] ^:"M=M;+R+IL#A41&50VPB!@<%%2D=9$
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MCOX&:1P\NR3I!^I)<@D[IB,VW;Z?'R^NX1>EP?3G;&/K3IN/?F1$]6([#3\72V,SLT^CLX2O^/OG_Z
MX2C.!A"OLG[G9.;!AYD^63SW@Z\/C]J=23KH?'Q^L)>&]O<_Y]/VZ6<#7/QR
M5#5Q?H6G43G@0^W:HYU0MZ SQ$D:7_7#DS3"**^3B](RTUF48R<+O(W925NY
MZ=R,_>JT^^X3].FM-T"PY%X$>[_2LO$Q?O:YO(RV?QS.IA$>P"71P>^?WDJ<
M9CIVY]]%]BG-WU[MOWO^K#IXM_ON^<%*LG>> 6L=;V_WW^T_
M/ZAV7SVKGO_7WB^[K_[QO-I[_>NO^P<'^Z]?E5DQB%F!^Y3FOW8/?ME_]8]W
MKU^-JF?;>]L5AHRJM+MQ-M%K;8JV=[\?KMK]55
MIG?7!T;!1%X_F4ZZX*6V7>#PXG<>D,:*$F"Y2Z.]_01P^_4P6;2HSN'?@
MT^YR,-:GTWD;;__1NZ>+1R'8"7#Y!9M2H2>-WVG\B9[IUE]TGMV]M]+SXP!F
MJZ>_KYNZJW$YW5E]?WE1O,J=2:Q['$L/B[)\TKIKKE"?7Q)_F'W^R*/%[%NZ
MGLL/N\$TS^?1XNNC>O+T0Q0 ,#.O_]CI_@3I%U?/__=^UM96CY?3(][D[(8+
M,2UO&=_ANAE[ _ZM9U6-?PP5)0-)':I>.@:* &LJ!5L0 BJ$-W$-D'.R+
M"_YSKF<1K,>G;_W)=-9N52%!:OOC5OUQ.:M!.YO?!UU<,Y;__2]*4/[T!L88
M7<&5AC2LV8_O9?8/C@C]\[?=M^^>OWWY[^KM\S>OW[ZKWOSV]N"WW5?OJG>O
MJX/G>^_V7[^J$*E>OZT0^\Y]7[U^4;W[Y7EU+EMWEJG;W7N7/D:*T*OFSLK#
MQK\33 P,:WLVO"NP]M$E"GME<2^FLZH]\M6?*^==+9:FJ\CSO;LI;7&KH5P#
M54H2'I3E\4Z0IC;5"$AN$0A1IIHAY(S$?4'5F^X=GR\*-RX"E8N_ Q-\T0]=7JB*YB6-<2ST>9=JV5_&_?EOB\*%S@Q*'ES@\
MBSC<(\D-P0Y GWKWIBTY!J, G)".6,.0-?VMR#,C;,R^^BLC#;'I\
MO\N(G72=M]-9MZEV)S[!S\;UQ*^/S%[Q?P^U,&AJPU"!&@4%[KOLJO[,>7-++LJE:K?YDS/D6[:H[^!
MP1KFG0)"IG/5E-9 .I@2"M)9:AGA@O7C;][ZP[I)1+1]%3^Y?Y]S.[%=-U=^
MV?M7]7,=AW58VZ;:G]CM=:;1RP+CLJSM^4=MVRI-H&H:JD]3JM)-=7#B;=J%
M[*IZ4M5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MJ+V0BFB?3E?@F@.*J0?IX 7 K*(&<:+3"&V_>Y(AV"U)RF(W<#C7.1*@'B5$R'4PFIF9;28;.NN8B'/A=3
M18&?65^]T;,_/NC3KP@T[\G!?654L:Y)A32'T:\!QXT&5*3CP0-3\0]G+?=<
MH:!ZG51[Z?R_V;OIA\&GXGZM9SJJ(BN-((L]2'5'&CXP2#
M6&JJI:*<]SH5N_S"Z]F;V?1]C($W/W?\(@ZH=CJWU/'"#SY:BAD(9RA !235
M+$YA'Q&=4P<\D4XQI[V7/15^+*?]FVF:I*.9E%MUZ?Z''E/WH[;^OWJ5@EU-8W):VY44J/SJQ*WNR+>7\J]_K[7SYBB-33IFK]V)\<32>^FG1KDJ,J&M]XGJJA*AU-)"*8\SO5
M=_=(* 7#$"JI08"$Q-B&VQ@PRVBWG&O#4N<)=&=D3>',;GR]3@F!S/?
MWV(5
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M.Y?W+I.7=:)/MS7J7BIY/#[M(H&>N[TAJ$J^Y8DZ;Z
M+MXO^JRJF^9:FYJOI\I^?.L[W[_D?8,6ZN/XUN?[D$J,W/*[;-OI//XY>
M<3:=)-8^/JU\9/"GU7[B$-IV=/=*L7O6P_0X9/]SA?3/%V'J^DD"V;Z\W'
MBZWY!^!=]5UJSRZ>8H*WEQ>T1W431ZQ/4H^]=$8KQGWM\WWV_?LVO71@:"
MJ0+>=!FH&-AJC0-@6%-KF43(H[Y:39TI,.EOZ>F'/].+:R^NO;CV:UU[]*:Z
M&D?!^$I;&UU[*CURG;>;)4Y\Y6^K:$7@R@^:^&;QQR6M3M[83H^C/$]'*02(
MMXN\.2GAL(I2_= >K3[>CA&![\;F?*@GW:D1W;Z619&L?7K=$!>?NZ=G%W[%
M)=\NS2% RL+K]FR&?7UI,%A"%L %X%..>CFNV-,L52%[A9=8$X.DY\4R]2
M=&.[4DRV%;^I#S)V6UTKFL,,CL.+?RPW*I@:@CH%@ @,4(92*CQ" 4',J%/-"N/X. ISM10)Z.)V=7E& U%W4
M45.[O.A>:I'63-)>794WS:T$+\\9/T!M+]=EBB*'KLB#ZQ8,BFKO Y6LPHH+
MS0$S7 &JJ0(*^@A26%!O+,*(R7Y0J5/TS_.FGOBFN8!*BPP]:&?S^]BA<<^.
MZ4ZM!$L*85#DNFBH:*AHJ&AHLS544@B;R,.?7UV)4UCXO6RM12I#UP(I6B
M!JV ]-(#B!61#FIA=4^EJ"LU_Z/3\MY"R86-9].#([/YGJ-. 3WLJV"ZL9EFP';Y0&)U:BU]9SUV'JW;I='MSO*LF
MTVYKS;Q9%%5'F?FH%U>E*YNNNGJU#R;MCTG/&I^FAW^HXZ/C8ZM)?(=IRGB^
MKYMNH6*B)[;6XU36EXX@3QYSIY[V$F&$@;$,1?<"
M.3!8&X"(LL(PS*SN:>G\($GJ"U%1T..F>)9,WJ)XEIXKE].NL$W9N?FK/JWD
MJ,(0D]%E-N?6XKX&**>EOWW1;4^.A'+)YZP.G$1O&2!.IWG2U.[+.> IY<$+
M+!2YE(]202HGXD4:8@XH1Q28H!Q0@7 4/;AS4EW1]:)K:=>U#SI(W=V:U_.V
MX[Z1!&]5\TF]N/UOOW>]WYJMB%RVC@)I?MR"%QWT9'X,W+0%RPNV?B)L)*4<
M(<)6#F[UEANS/7E#WF.AVT0_[*+#89/FP^A3[[^S;H!G70!'U?331-G^&B"
MMVH6=;M ^F*S*+R-V4E;N>G/LD+>NKFW-K$CK6Z5U=+:D>*(/
M_2)-"W1H_6Q'CS_HT^;I5O4D-[G>D"9$EPGFO>0)UR^,#3F4Z/E_O7FY^VKW
MW>NW_ZY>O7[WO)PT=.K7HU
MW:Y02JRG2/&7O7]5/]=QT(>U;:K]B=VN_CG7J<'5^+1:].>K(DE]$4=8(0C^
M>=:I\,_%5=5B/>!7/;-'%4&K('31\#_UP9K.ZCB!N@Y?BX:.W=+ 9[T;4YN4
MLTQ<"I/JIDD16OQ?BFW5XK;5=^EKJW8JKYS^#;U)#[[J#9U&U]@&RT'<_8+O)U2@-,N
MX;@]
MR,XD_&1WT4/R\]]&3ATEE19D=%+EJ)J?N)0:G9X-*R4\%^.,\^TXB;YR=6/'
MTV:>0HXT(?0J$YI&\)D$MZLO391/,R#=IY[,XQU3:[.32%HJW:SRJ8LAA:ON
MW[W5V4O,?!@O5-*U?DM-,+M6:E-K4\LP5^G%9\W<-/[/>1I/NO=V]0V)O!X\
MT2:E!Q\*$#+%QSSY:11NO5G6Q(PSP$;VR&)]F-E] ;K_B\YUZ&9^P^W.E[0S[?
MK6BH:.B3ABZNP\%M=G9LRY4D_(&TV3G/!TBB]ZKK-Y'GYZONO$SU!F[=JUXN
M4>L\]_&EL\DRVT0Q.*;_9O?MNVI_^XY6>%[R2XZZ'K6"Y=TO;+(YSXK7K6Q=
M'3N==;GQG?@4/QO7$[^V"?)B_]7N
MJ[W]W9?5_JL7K]_^NOMN__6KL^FB'\YQWQZ-US ][@V.UYR30P\-QYGY\X?-
M:!78W=S"Z?W6'U>H ._M@1=O./">;?%+I_HMSCA'77^\)N)[R[H^= :*.A9T'-ST?-R0$HV.R#]68\C
MJOK4&<*74+2$H@5,"YCFHZ8<3:F Z>W!E&XVF'[*Z::H='KB%T\NL+JIL(H+
MK!98+;!:8/5A894])EA=[.=-NX>KKCO0T70/3INX"WT_;=?:F$[]_IG,AZQA2UN_][Q&ITB_&JW^G
M?L>;#>__//?Z'5#_\]/K=SB_:O>\:Z;S-NT"^L.WU=NZ^:. ]X:"-RZESP6\
M"WC?&WC3 MZW V_Z>Y+D;#IN.N ^F4VM=PFL-ANR]Y8OW<'UF[.7+GA<\+C@
M<<'C;-0TN%X*BR:0I0OD7;I ;G@;R-?O?GG^MK2 ? RH6W8J%=0MJ%MZ0 X"
M=C>\">1+?ZC'BUC7)YF78+? ;H'= KOYJ&F IK: W=V"NW? W0WO=976>:L7
MVK;368'< KD%<@ODYJ.F 9I:J;:^,^)N>$.LWR8S?U@W$=J\JP[TV' +@!= #H?-0W0U$HU]9T!>L-;:SWS
M07<[F7X[F4XB(D_JZ>P<,!<0+B!<0+B <#9J&J"IE:KH.X/PAC?;^C7>/$;'
MP<>@^-PFI0*^!7P+^!;PS49- S2U#GQ9 =\[@.^&M^1ZW1[Y6;4_"6D Z9D%
M=@OL%M@ML)N-F@9H:AWL\@*[=X!=N=FP^_SC46WJTO1R<]&V-,T:/MI&O:0[
M_+B%MQX+\E[ABM5FN^*#^/JZ/9]Q//^R=WN;=8VY*KBQJ;A13B+(&C?BW]J,
M???C=6+ZVV.3TNV%P>\JC$^>9^"&7]>?"?3HC)^YY_]#L3Z=SMMX^X\^
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MAMB7(LLFN/ZPKV>=Y+_?-"BFLQ)>%]!U",AX6O>B+XW
MG\WB3Y5N&M\V.WD$QIFI-1,;S"8755QE7HG;HIIL55,\6?%DQ5R*:C+FXQ=#
MJO,RQHL[]4?1S^\4Q^?D75C[M[)VW1QUYXC:](/_/+,(2
M1WT+00#%F /#+0&:<(,QX8X'LE5U=_G8ODU==O=^YP19@ST&E@4#J&,:: XM
MX,I+RAG#6M*M:J*/HZ#G#3C4^F0G^?K=B4M_/?_DZ'?;/3V;G=:3P__4X[G?
MJN:3>O&4WW[_[>#95N6\K:-0FA^WX%:U.._CQZWZ8Q36_!BX:==V-UV0CHH8
M$!&P6_\]##D"9^P>^"WYN$WX%S+ ,,@#NF (5,
M (6A!YIZ1X)T1+KP.7Y[%Z2!P@%D)0)4>06,1"];]5#\9!E
MH:'PM%OQ-(H=P]I"P(4C@ IB@8$A$B]" @H*:D0O\;3;Y%DZ/_TNNNG]3U[Z
M+K1,C01A(T5@7ZRL^)QA^YS,1%[ -@>3L,[/.X?"RDB;.7."%EPW/5U[-RZ FU+%(JIS"!E"#.-!,>R"P<$QX
MYS%E?21!WIXYZ.:5;Y>;@^Y"S"@2(ZY869DJ+B=#D1>LS4$+&R'P@K6;@K78
M& &U9 !RK0%E% ,55'PK2*33@@5D>!\YD-ZQ-LU5@67!VAQ=3JD">=0ID#" 9B !' "
M":^P)YK1/E(?2P_]?.&@>Z!C:$04':ET4$!9DRI.)SN1%[3-00L;(?""MIN"
MMEY 1!V"0&$6T59R"20A%'BG W3*HCI=)Y_=W.V??!\!0?091G*ES,I""]!N'],9R%;!40%GK(](3!@PS%!"#H>980V5U'^F(#Y2
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MQ>44K"U8^_!:V B!%ZS=%*QU+ECM'06$0 =H( BD,@_ -;4D_L.C&)-.3*-?3474RUJE 8^*Z X5/DD7?I4MK647*@PF4O&[F
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M $^YHBS^YW0O!R,ON.2=3D+F(PG5"+'>,D;WZ_L*C=D7UP!/(B!$Z8K3PA$WA":6"
MZ*$2268Z=FOS-"_W=W_>?[G_;O_Y0;7[ZEEU\.[UWG_\\OKEL^=O#_[^EX\8
M(O6T>O[/W_;?_3N/!97,%)X3>XQ23Y_\N(6WRL[J?-545%-44SQ9\63%7(IJ
M,F?JI?U"-/W'RG3SBY,QTFXDAEK32(/QE22L5U11/5CQ9,9>BFB&0\NMW
M3N'%G=:SA[M\X,7:MC>-MF^I$GVHS]GF$U 7LMGIM'3Q;Q8>OH>S*M$(8SY"
MK/0W_ JWM1$X4? Z#ST,:>(7O"YXO4EX[1AW3&($B$084(8Y4-"FPY@D9HH3
MQ1#N91&O :<3IB'!>\SA&OU[8N6E(P0_ VT=YG<^_.KYYVAS9-NV[&]O+:
M:AX9ULS,=CB1 GH,L'*"Q=]A
M8OII3G.1 NY.W*+_X0(ISI6^]T(.!8$C@DO?X^+H"A/(6@^%"62JF,($'AL3
M<$1I9Y0&B"8F@'UD M1;X!0E04%%C;S$!'I(!JV5"9 186)$:&_+.H4);$I>
MJ31%'I[C6C1%[B]_5-8,\R G)?F>N<#+DM_PG.75+(]S3 SF C@4N1T-& &=
MSB2UFCF-"/%673J)]#;YGGYY'!XIQD=4HK+<5SQ.AB(O4)N#%C9"X 5J-P5J
MM9):8XJ!L-(!"CD$.E -F#3(<:=09
MD&?>M*-JXML\E@$R,\?AT+!>\\B9:6$C!%YHV/"G?I6(5;93RFD\-W?G:<7/1="!@?1:HWDHIDN695?$T!V0*R
M#Z^%C1!X =E- 5E'/$.!0:"P3KD.2H!6B ")J;(N$&6([277T1O($LE'F.1Y
M6O:C]S6EAW)U2HN-/:4AS*8PP9(-SUS@9>5M>$[R:N;F _2&60><\!10Q! P5EO
MD!"&*$P
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M3,>9&&0YU'P0?K,DP8MJBB++BR8JY%-5DS,9+/^&AKZG5*_>?JD%Q)
M'+&> .(M M1K!R1U"GC(E-=:(N4N=7*_S1Z+A3:Z18XW>O9Z=M#JUKO_U..Y
M?^-G!T=ZYB_6A<8?O>NN:EZ'W>/X:E8_FX['>M8LK_Y4-;K_ZL4-=:-7OWP0
M5FCD&?">JG1"L '*P/A>3L(@ @N*]G(NX ._?)Q&$%YUOLPU%;0#-_P%(ISH
M6?4^2?AI51S EXYR$-AX2C6@@8?T!P:*
M'DUG\37=A;G?=!]^TPE*+ H8=O]M]I1>B*;29X+[P\\E%QX1
M2D7/#.<;O?O-D_VQ^?=KO?J92*OBX&^:]T1AJ[0%U 89F7WT[8H(#4B]E1GLK2R%
M'V4?][6 AT7@,2XAP 8? 8];!B3R'G#BO55,0'9'+2P$0(O(+LI(!L"@0+1"*U$0D ADL @RD$@U$K.M;ER=Z-I% 596G]2M'N=10I29AH?#M0*PRHY1)H+B2P1 >DI;8*\3X2&I]\]9OHJOPM'?1?*)?%(\?1?;T '<30%<9+067@3@ HR
MZU0 6O#4.9)P@SE31E^J!+Y-LVCZ1Z9JH=#N'J-<-;#CK,=M5I.K#Q-IF?M[[5]<2[YWHVJ2>'S3DP>[;
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M&E A.9".""!UT%Y#A:6_M(/\-GFFGL$>I\/ 1PJ+ O8;XXVV%]I:Z?'\<5.Z\EA-9FV\;[MM&J/
M?/1.>N[2N4+)%T9A-_&G.LFB/JY"/=$36W=U6+KUQ_%^S?955;G#$$25QU2[
MRNYZ$F"?UMF/M/BC,\SKY(D^D^?1V3K&B3[T"Q@&.L27W='C#_JT>;I5/]F@5=C-%^1!)3
M@7^G0Y\5>V?(?W"&\]4T5*]/_$RG<*,IL^3Q^8KO?EM1P^^+^@>/FUVX>55=
M@IZWTU4HGP88(X0=^+2['(SUZ73>QMM_].[IXE$(=A)E.99CVE84
MWW@-O.D*N0TYO?MM\A[,%PIIY+?5T:RO)]S*@KXJ523OR7_?8,(RFY6/!RIZ
M[E\/MW"D]ZF%*//TR8];?"O[*MLL+>H>&%&O\^'=TAYEMSQI
M]^QPNCP,]IN+2W.?)QG9?/&\#ZR%0E^*$14CZI6^X$)?'@5]2>>BYV&3A:$4
MYUJ<:W&NF^5<;WLL>7&NQ;D6YUK.1LQ[@^=:5^[>^O=^,O?-SK L+Y/%P_O<
M=/%@Q";_TON6Q0S8S
M?69B?/>]WS(S+92]Y1O!*.ZJ@ $ZUZMWC#,L'9*! ZLI!30P!8SD!CC")5(R
M2$@O=3H,Q%GNO0+:20FH\18HQ#S05COKI8/:7G&B1N?:7\RFQWOQ9FD0_ZK;
MH[UY$Y7F9_L3.YZ[>G*XVS0^_L^]TQ_OU IQA)#(=@]Y9CYM(T"D@'D>>AC2
MQ"]@7L!\D\ \HJ\F(H(Y81&3*4,8:.Q#Q';(M>2.6NLN-9!C0E,)'2#&AD@
MC 5:1# G&B%&3<3_P!\8S"D:24D*DA"9(I2#U^2FBF['J#/+(?H?K%))/4":IC" F< -2YE[H@$ 0G.
M,($PZ$M1PFU2?@FY7H=EK' 7_H]&!,L1%.4,LTPXT3U.X2M/R2U\I_"=PG<*
MWRE\I_"=F_D.QLAY(RE0WD7N0JT&$EH"/)80"0RU)J&/K&AO? >K$6&PD)U"
M=@K9R8?LW,MA?'AQI_4